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1. INTRODUCTION 
One of the most intriguing and fascinating field of research in past decades is related to 
the embryonic development of mammalian species. The masterplan for the generation of 
highly complex organisms is laid out at the earliest time points of embryonic development. 
Despite its obvious importance, we currently have a limited knowledge of cellular dynamics 
and morphogenetic mechanisms of the human embryonic development (Nowotschin and 
A. K. Hadjantonakis, 2010). This is partly due to the fact that research of human embryo 
has limitations, such as ethical restrictions and the “14-day rule”, which does not allow the 
in vitro culture of human embryos beyond day 14 post fertilization (De Wert and Mummery, 
2003; Aach et al., 2017; Pera, 2017). 
Therefore, the mouse model is a popular and powerful tool for the research of embryonic 
development, without the limitations mentioned above (Taft, 2008; Sozen et al., 2018). The 
study of mouse embryo has already provided important information about general 
mechanisms of differentiation, as well as mechanisms that are associated with the 
pathogenesis of diseases, and which can partially explain defects in morphogenesis and 
organogenesis (Bedell et al., 1997; Bedell, Jenkins and Copeland, 1997). The embryonic 
development of the mouse is initiated with the fertilization and is strictly correlated with the 
age of the embryo. Not only the number of precursors from germ layers and the polarity of 
cells are important, but also the balance between proliferation and differentiation is 
essential to ensure the correct timeframe of embryogenesis (Takaoka and Hamada, 2012; 
Blanpain and Simons, 2013). 
Unfortunately, the definition of the precise timing of mouse embryogenesis in vivo is limited 
by the fact that fertilization occurs within the oviduct, and is thus not accessible for 
experimental assessment (Kojima, Tam and Tam, 2014). But in recent years, the progress 
in genetic manipulation, an enhancement of ex utero cultivation, as well as the option to 
permanently cultivate pluripotent embryonic stem cells (ESCs) in vitro have provided new 
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opportunities and methods to fill these knowledge gaps (Nowotschin and A. K. 
Hadjantonakis, 2010). 
1.1 Early embryonic development of the mouse 
1.1.1 From fertilization to the implantation of a blastocyst 
The embryonic age is referred to as days post coitum or “Embryonic Day” (embryonic age). 
As the total cell number of an embryo will be doubled after each cleavage cycle, the 
embryonic age can be assigned by both cell number and cleavage cycles. As such, the 
embryo including 2 to 4 blastomeres are at the second cleavage division the embryo with 
8 to 16 blastomeres are at the fourth division, and so on (Kojima, Tam and Tam, 2014). 
The early development of the mouse embryo starts with fertilization, i.e. the merging of the 
male and female germ cells (Johnson, 2009; Saiz and Plusa, 2013). In this step, the one-
cell embryo undertakes cleavage cycles to generate a blastocyst that contains three cell 
types: the trophectoderm (TE), the epiblast (EPI) and the primitive endoderm (PrE) (Figure 
1). Subsequently in the pre-implantation stage, cells will be located and segregated to 
these three lineages at different cleavage divisions (Figure 1). 
The implantation of a blastocyst into the mother’s uterus represents the next crucial step 
(BAI et al., 2013) and requires a large number of genetic and cellular interactions (Wang 
and Dey, 2006). Implantation is composed of three sequential stages: (1) the blastocyst 
contacts the endometrium (apposition), (2) trophoblast cells attach to the receptive 
endometrial epithelium (attachment), and (3) trophoblast cells cross the endometrial 
epithelial (penetration) (Smith, 1980). In the post-implantation period, the inner cell mass 
(ICM) grows into the blastocyst cavity to form the peri-implantation epiblast (Figure 1) 
(Tam, Williams and Chan, 1993). At this stage the embryo is called egg cylinder and forms 
a cup-shaped aggregate containing two germ layers, the inner epiblast (EPI) and the outer 
 8 
 
visceral endoderm (VE) (Figure 1). 
Fig. 1: Scheme of early embryonic development 
Scheme shows features of the mouse embryo at different embryonic ages, from zygote to gastrulation 
(E0.5–E7.5). Abbreviations: AMN: amnion, AVE: anterior visceral endoderm, BC: blastocyst cavity, 
DVE: distal visceral endoderm, ECT: ectoderm, EPI: epiblast, ExE: extraembryonic ectoderm, ICM: 
inner cell mass, MES: mesoderm, N: node, NF: neural fold, PAC: proamniotic cavity, PrE: primitive 
endoderm, PS: primitive streak, TE: trophectoderm, VE: visceral endoderm, ZP: zona pellucida. 
Adapted from (Kojima, Tam and Tam, 2014). 
 
1.1.2 Gastrulation 
Mouse gastrulation, a constantly evolving 3-dimensional process, transforms two germ 
layers (EPI and VE) into three layers which are the ectoderm, mesoderm, and endoderm. 
To achieve this transformation, the primitive streak (PS), a transient embryonic structure, 
is formed during gastrulation. At this stage, epiblast cells ingress into the junction between 
the epiblast (ectoderm) and endoderm to form either the mesoderm or the definitive 
endoderm germ layers. (Parameswaran and Tam, 1995). All three germ layers are 
partitioned into domains of progenitors, which give rise to specific organs or body parts. 
During this ingression process, epiblast cells with an epithelial phenotype lose specific cell 
surface proteins through an epithelial-mesenchymal transition (EMT) and differentiate into 
mesenchyme (Rivera-Pérez, Mager and Magnuson, 2003; Mikawa et al., 2004; Migeotte 
et al., 2010; Nowotschin and A.-K. Hadjantonakis, 2010). 
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1.2 Stem cells 
Stem cells are defined as toti-, pluri- or multipotent cells which can differentiate into multiple 
cell types, and have self-renewal capacity to sustain the pool of stem cells. Two major 
types of stem cells are found in mammalian: ESCs isolated from the ICM of blastocysts, 
and adult stem cells (ASCs) from various tissues. Although this definition of stemness 
generally applies to stem cells, it is still necessary to individually characterize embryonic 
and adult stem cells, because of substantial differences between these cell types. 
1.2.1 Embryonic stem cells 
Fig.2: Scheme displaying the stem cell hierarchy 
ESCs are pluripotent cells that maintain the ability for differentiating into three germ layers: endoderm, 
mesoderm, and ectoderm. Adult stem cells (ASCs) such as hematopoietic, neural and mesenchymal 
stem cells are multipotent stem cells which maintain a more limited capacity for differentiating to specific 
lineages. Adapted from (Hayes et al., 2012). 
 
ESCs are isolated from the ICM of embryos at the blastocyst stage. The characteristics of 
ESCs relate to their self-renewal ability in vitro and their capacity of differentiating into 
multiple cell types in vitro and in vivo (Figure 2). Following derivation of the first mouse 
ESCs in 1981, researchers concentrated on the study of stem cells to define the 
pluripotency of ESCs (Evans and Kaufman, 1981; Martin, 1981). In vivo, mouse ESCs 
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exhibit a capability of colonizing somatic tissues in diploid aggregation chimeras and 
support the complete fetal development (Nagy et al., 1990). In vitro, the differentiating 
capacity of ESCs into different tissues is validated by forming embryoid bodies (EBs) that 
include 3 germ layers (Jaenisch and Young, 2008) (Figure 2). Moreover, the ability of 
ESCs to differentiate into different specific cell types such as cardiomyocytes, liver cells, 
and osteoblasts is confirmed by several guided differentiation protocols (Buttery et al., 
2001; Boheler et al., 2002; Rashidi et al., 2018). 
1.2.2 Adult stem cells 
Adult stem cells (ASCs) are undifferentiated cells that are found in the body after embryonic 
development, which bear a potential to differentiate in a lineage-specific manner. As such, 
ASCs have a more restricted ability of self-renewal and differentiation. Multiple types of 
ASCs have been isolated from adult tissues, which are responsible for replenishing pools 
of dead cells (Moore and Lemischka, 2006). Mechanisms to regulate ASCs are strongly 
associated with their microenvironment, defined as their niche. Niches are locally restricted 
areas consisting of other cells, extracellular matrix, and signaling factors (Fuchs, Tumbar 
and Guasch, 2004). Moreover, stem cell niches can dynamically regulate the balance 
between self-renewal and differentiation of ASCs (Morrison and Spradling, 2008). 
The best potential for the application of ASCs in clinical trials relies in the restoration (in 
cell therapy protocols) or replacement (in tissue engineering approaches) of tissues that 
have been damaged by disease or injury (Pessina and Gribaldo, 2006). Hematopoietic 
stem cells (HSCs) and mesenchymal stem cells (MSCs) are the most widely used ASCs 
in this respect. HSCs are used for bone marrow transplantation, while MSCs are attractive 
for clinical therapy because of their ability to differentiate into specific tissue types, such 
as bone, cartilage, tendon, and ligament (Beyer Nardi and da Silva Meirelles, 2006). 
Moreover, adipose-derived processed lipoaspirate cells were identified as a viable clinical 
alternative to MSCs. (De Ugarte et al., 2003). 
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Although many studies on the therapeutic potential of ASCs were performed for non-
hematologic diseases, there are three major problems: ethical issues, immunological 
rejection, and the potential of developing teratomas (Moore and Lemischka, 2006). 
1.2.3 Stem cell markers 
in the past decades, different transcriptional factors have been identified as important for 
the pluripotency status of ESCs. Regulation of these transcriptional factors occurs through 
a network that can regulate their own expression and that of other key transcriptional 
factors. A network of three transcriptional factors Sex-determining region Y-Box 2 (Sox2), 
Octamer 3/4 (Oct3/4) and homeobox transcription factor Nanog plays central functions in 
the maintenance of pluripotency. These factors continuously inhibit the expression of 
lineage-specific genes and maintain the expression of pluripotent genes (Boyer et al., 
2005; Loh et al., 2006). The working patterns of these factors are not independent to each 
other, but they are rather involved in an complex network, in which further downstream 
factors such as Esrrb, Rif1, and REST are implicated as well (Rodda et al., 2005; Loh et 
al., 2006; Chen et al., 2008; Thomson et al., 2011; Rizzino, 2013). 
Apart from transcription factors, various cell surface receptors command the regulation of 
ESCs pluripotency. For example, three monoclonal antibodies are used to identify stage-
specific embryonic antigens (SSEAs) SSEA-1, SSEA-3, and SSEA-4 (Solter and Knowles, 
1978; Shamblott et al., 1998). These molecules are involved in cell surface interactions 
during embryonic development. SSEA-1 is expressed in pre-implantation stage of mouse 
ESCs, as well as in germ cells. However, it is absent in human ESCs and human 
embryonic carcinoma cells (Knowles, Aden and Solter, 1978; Solter and Knowles, 1978). 
Numerous types of surface receptors such as epidermal growth factor (EGF) receptor, 
leukemia inhibitory factor (LIF) receptor, Epithelial cell adhesion molecule (EpCAM), and 
bone morphogenetic factor (BMP) receptor are highly expressed in pluripotent ESCs 
(Bhattacharya et al., 2004; Skottman et al., 2005; Adewumi et al., 2007; Assou et al., 2007; 
 12 
 
Lian et al., 2007). Notably, the expression of EpCAM displayed a spatiotemporal regulation 
in ESCs. EpCAM functions as a growth factor receptor and an adhesion molecule, which 
shows a high expression in mouse and human ESCs, porcine induced pluripotent stem 
cells, and in the vast majority of carcinomas (Lu et al., 2010; Ng et al., 2010; Huang et al., 
2011; Yu, Ma and Wang, 2017). 
1.3 Epithelial Cell Adhesion Molecule 
EpCAM was initially described as a protein on the cell surface, showing a high expression 
in the majority of carcinomas, including colorectal carcinomas where it was first described, 
as well as in acute myeloid leukemia (Herlyn et al., 1979; Chadeneau et al., 1991; 
Bergsagel et al., 1992). Today we reckon the expression pattern of EpCAM as limited to 
pluripotent ESCs (González et al., 2009; Lu et al., 2010; Ng et al., 2010), hepatic and 
pancreatic progenitors as well as other endodermal progenitor cells (Schmelzer et al., 
2007; Kamimoto et al., 2016; Maimets et al., 2016). Additionally, EpCAM in fully mature 
cells is expressed in sub-types of normal epithelium composed of adenomatous layers and 
supra-basal layers of the squamous epithelium (Balzar et al., 1999b), and in malignant 
cells such as carcinomas and cancer stem cells (Gires, Klein and Baeuerle, 2009; van der 
Gun et al., 2010). Other matured cell types are completely devoid of EpCAM. This selective 
expression shows a strong dynamic and tight control of EpCAM expression during the 
differentiation of ESCs into mature cell types. However, knowledge remains very scarce 
about the principle and accurate timing of this dynamic expression pattern of EpCAM 
during ESC differentiation. 
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1.3.1 The EPCAM gene 
The EPCAM-encoding gene, a member of the GA-733 gene family (Szala et al. 1990, 
Alberti et al. 1994), is characterized by a high sequence conservation across various 
species. The human and mouse orthologues of the EPCAM gene have a homology of 80 
percent (Bergsagel et al., 1992). While human EPCAM (hEPCAM) localizes on 
chromosome 2 (chromosomes 2: 47,572,297-47,614,740), mouse EPCAM (mEPCAM) is 
encoded on chromosome 17 (Chromosome 17: 87,635,979-87,651,129) (Figure 3) (Szala 
et al., 1990).  
Fig.3: The human and mouse EPCAM gene 
The EPCAM gene consists of 9 exons. The first exon encodes the signal peptide, exons 2-6 encode 
the extracellular domain (EpEX), exon 7 encode the transmembrane domain (TMD), and exons 8-9 
encode the intracellular domain (EpICD). The EGF (Epidermal Growth Factor)-like domain is encoded 
by exon 2 while the thyroglobulin domain (TY) is encoded by exon 3. Adapted from (Schnell, Cirulli and 
Giepmans, 2013). 
 
Both, the mouse and the human EPCAM gene consist of nine exons in total. Exons 1-6 
encode the extracellular domain of the EpCAM (EpEX), including an epidermal growth 
factor (EGF)-like domain, a thyroglobulin (TY)-like domain, and a cysteine-depleted region, 
as well as the signal peptide. The signal peptide (SP) is ultimately cleaved off from the 
protein, but is essential for the transport of EpCAM to the endoplasmic reticulum and, 
eventually, to the plasma membrane. The transmembrane domain of EpCAM (TMD) is 
encoded by exon 7, and the exons 8-9 encode the intracellular domain of EpCAM (EpICD) 
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(Figure 3). 
1.3.2 The structure of the EpCAM protein 
The mouse EpCAM protein is composed of 315 amino acids (AA), the human EpCAM of 
314AA, which are subdivided into three major protein domains: an large extracellular 
domain of EpCAM (EpEX), a single transmembrane domain (TMD) and a short 
cytoplasmic domain called EpICD  (Balzar et al., 1999a; Munz, Baeuerle and Gires, 2009) 
(Figure 4). EpEX includes an EGF-like domain and a thyroglobuline (TY) domain. EpEX 
contains three different N-glycosylation sites at asparagine residues Asn74, Asn111, and 
Asn198 (Thampoe, Ng and Lloyd, 1988; Schön et al., 1993). Glycosylation of Asn198 
contributes to surface expression and protein stability of EpCAM, which was demonstrated 
by selective mutations of these glycosylation sites (Munz et al., 2008).  The crystal 
structure of the extracellular domain of human EpCAM has been resolved by using 
standard chromatographic techniques (Pavšič and Lenarčič, 2011). Furthermore, by using 
mutants of EpCAM within the intracellular domain EpICD, two potential -actin binding 
sites were determined at positions 289 to 296 and 304 to 314, which are essential for 
EpCAM location at cell-cell adhesion (Balzar et al., 1998). 
1.3.3 Regulated intramembrane proteolysis (RIP) of EpCAM protein 
Cleavage of EpCAM protein is fulfilled through a complicated process termed regulated 
intramembrane proteolysis (RIP), which plays an important role in the post-translational 
processing of numerous transmembrane proteins (Medina and Dotti, 2003; Lal and 
Caplan, 2011). RIP is involved in initiating cell signaling via surface receptors such as 
Notch family members (Schroeter, Kisslinger and Kopan, 1998) and EpCAM (Maetzel et 
al., 2009; Chaves-Pérez et al., 2013).  
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RIP of EpCAM firstly releases the soluble extracellular domain EpEX by the proteases 
ADAM10/17 and BACE1. EpEX act as a ligand for intact EpCAM molecules that could 
induce further cleavage (Maetzel et al., 2009), as well as novel ligand for EGFR in colon 
and head and neck carcinomas (Liang et al., 2018; Pan et al., 2018). Thereafter, the 
EpCAM C-terminal fragment (EpCTF) is further processed to an A-like fragments and the 
intracellular domain EpICD by -secretase (Maetzel et al., 2009; Hachmeister et al., 2013; 
Tsaktanis et al., 2015) (Figure 4). Among these fragments, EpICD can form a complex 
with other molecules and translocate into the cell nucleus (Figure 4), which further plays 
important roles in cancer cell proliferation and stem cell pluripotency maintenance 
(González et al., 2009; Maetzel et al., 2009; Lu et al., 2010; Huang et al., 2011; Chaves-
Pérez et al., 2013). However, pace and efficiency of the generation of EpICD from full-
length EpCAM by -secretase and the actual stability of EpICD, which is critical for 
understanding the accurate timing of EpCAM regulation, remain largely unknown. 
Fig. 4: EpCAM undergo regulated intramembrane proteolysis 
EpCAM is firstly cleaved by ADAM10/17, releasing ectodomain (EpEX). Following the first cleavage, 
EpCAM intracellular part (EpICD) is released by the -secretase complex. EpICD form a complex with 
FHL-2 and β-catenin, then translocate to the cell nuclei. Adapted from (Schnell, Cirulli and Giepmans, 
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2013). 
 
1.3.4 Molecular functions of EpCAM 
The name of EpCAM stands for epithelial cell adhesion molecule, which describes a cell-
cell adhesion function. Accordingly, EpCAM was initially shown to provide epithelial cells 
with a weak cell adhesion through homophilic interactions (Litvinov, Bakker, et al., 1994; 
Litvinov, Velders, et al., 1994). However, the cell adhesion function of EpCAM has been 
questioned recently and is a matter of debate (Tsaktanis et al., 2015; Gaber et al., 2018). 
In contrast to E-Cadherin, which involves tight connection via adherens junctions, cells that 
express EpCAM in the absence of classical cadherins are only loosely connected to each 
other. Notably, when EpCAM is co-expressed in E-Cadherin-expressing cells, it weakened 
intercellular adhesion mediated by E-cadherin (Litvinov et al., 1997), suggesting complex 
and intricate functions of EpCAM in cell adhesion. 
In vertebrate epithelial cells, the tight junctions (TJs) together with basally localized apical 
junctions will form the apical junctional complex (AJC). Through electron microscopy, 
researchers found that EPCAM-mutant zebrafish exhibited a reduced expression level of 
E-cadherin in enveloping layer cells (Huang et al., 2018). Moreover, EPCAM-mutant mice 
displayed a scattered and dispersed TJs in the intestinal epithelia (Lei et al., 2012). All 
these evidences suggest EpCAM could affect epithelial integrity and lead to dysfunction of 
AJC and TJs. 
RIP of EpCAM induces the release the intracellular domain EpICD and further activates 
the downstream signaling. EpICD is translocated into the nucleus in a complex that 
contains additional proteins including four and one-half LIM domains protein 2 (FHL2), β-
catenin, and lymphoid enhancer binding factor 1 (Lef-1) (Figure 4). In cell nuclei, the 
EpICD complex can bind to promoters of target genes such as cellular myelocytomatosis 
oncogene (c-Myc), an oncogenic transcription factor, at Lef-1 consensus sites (Maetzel et 
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al., 2009). In colon carcinoma cell lines, activity of Lef-1 and c-Myc was inhibited after 
EpCAM knockdown while enhanced expression of EpICD was able to counteract those 
deficiencies (Münz et al., 2004). Induction of EpCAM expression causes an upregulation 
of the cell cycle regulating proteins Cyclin A and E, as well as epidermal fatty acid binding 
protein (Münz, Zeidler and Gires, 2005). Oppositely, repression of EpCAM in squamous 
cell carcinoma (FaDu) cells lead to a decrease of proliferation (Maetzel et al., 2009; 
Chaves-Pérez et al., 2013). Similar results were found in breast cancer cells, where 
inhibition of EpCAM expression led to a reduction in proliferation, migratory and invasive 
capacity (Osta et al., 2004). Therefore, these evidences suggest an important role of 
EpCAM signaling in cancer cell proliferation. 
1.3.5 EpCAM related diseases 
EpCAM plays a role in Lynch syndrome (hereditary nonpolyposis colorectal cancer, 
HNPCC), an autosomal dominant disorder that predisposes to colorectal adenocarcinoma 
(60–90%), endometrial carcinoma (20–60%), and various other cancers (Ligtenberg et al., 
2009; Kempers et al., 2011; Kuiper et al., 2011). In a total of 45 Lynch syndrome families, 
19 deletion mutants of the EPCAM gene have been identified (Kuiper et al., 2011). About 
20% of Lynch syndrome cases showed a loss of DNA mismatch repair proteins, because 
mutations in the 3’-end of the EPCAM gene result in epigenetic silencing of DNA mismatch 
repair gene MSH2 (Rumilla et al., 2011).  
Lack of EpCAM was also found in patients suffering from congenital tufting enteropathy 
(CTE) (Sivagnanam et al., 2008) which is a rare autosomal recessive disease that can 
cause intractable diarrhea during infancy. CTE patients suffer from chronic diarrhea within 
the first days after birth and exhibit an impaired growth. At the cellular level, EPCAM 
mutants associated with CTE displayed an abnormal localization within intestinal 
epithelium and a disorganization of surface enterocytes with focal crowding (Sivagnanam 
et al., 2008). Several EPCAM gene mutations were identified in CTE patients, which can 
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cause single amino acid exchange, truncation, or partial deletion of the EpCAM protein 
(Sivagnanam et al., 2008, 2010). A pathological absence of EpCAM may break the 
required balance between stem cell proliferation and differentiation, which ultimately 
affects the normal intestinal epithelium development, integrity, und functionality 
(Sivagnanam et al., 2008). 
1.3.6 EpCAM in stem cells 
In mouse ESCs, maintenance of self-renewal is associated with a high-level expression of 
EpCAM. Cultivating mouse ESCs in the absence of LIF, which is required for the 
maintenance of pluripotency, results in a down-regulation of EpCAM expression together 
with the expression of c-Myc, Sox2, Oct3/4 and signal transducer and activator of 
transcription (Stat3) (González et al., 2009). In presence of LIF in the culture medium, 
repression of EpCAM induced an ESC differentiation, suppressed proliferation, reduced 
alkaline phosphatase (AP) activity, and Oct3/4, c-Myc, and SSEA-1 expression. In 
addition, differentiation of mouse ESCs could be partially counteracted by forced 
expression of EpCAM, which increased Oct3/4 expression and ESCs proliferation, 
suggesting important functions of EpCAM in ESCs fate regulation (González et al., 2009).  
In human ESCs, chromatin immunoprecipitation (ChIP) analysis confirmed the direct 
targeting of the EpICD to promoters of several reprogramming genes, including Oct3/4, 
Nanog, Sox2, and Krüppel-like factor 4 (Klf4), which could further help maintaining the 
pluripotency (Lu et al., 2010). Thus, EpCAM is closely associated with the maintenance of 
the pluripotent state of ESCs. 
1.4 Objective 
The dynamics and expression patterns of EpCAM has been well studied in cancer cells, 
and plays important roles in the regulation of cellular fates along the epithelial-
mesenchymal transition. However, the regulation of EpCAM expression patterning during 
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non-pathologic process, e.g. during ESCs differentiation and in processes of regeneration 
of adult cells in organs such as the liver, remains largely elusive. While EpCAM is strongly 
expressed in pluripotent ESCs, it is only expressed in few mature cell types including 
primarily epithelia and malignant progeny (i.e. carcinomas). Therefore, knowledge of 
EpCAM regulation and timing of its expression and degradation during ESCs differentiation 
is required to comprehensively understand the EpCAM expression patterning in non-
pathologic processes. Besides classical transcriptional regulation of gene expression and 
post-translational regulation of protein stability, EpCAM is subject to RIP, which can further 
feed into its regulation at the protein level. However, the cleavage pace and degradation 
efficiency of EpCAM, which determine the regulation timing, remain largely unclear. 
Therefore, the first goal of the present thesis was to define and characterize the EpCAM 
expression patterning during ESCs differentiation. The second goal of the thesis was to 
provide an in-depth characterization of the cleavage pace of EpCTF and of the stability of 
EpICD. 
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2. MATERIAL 
2.1 Chemicals, consumables, and equipment 
2.1.1 Chemicals and kits 
2.1.1.1 Used chemicals 
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2.1.1.2 Used kits 
 
2.1.2 Consumables 
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2.1.3 Equipment 
 
2.2 Media and Buffers 
2.2.1 Cell culture buffers and media 
PBS: 8.0 g NaCl, 0.2 g KCl, 1.15 g Na2HPO4, 0.2 g KH2PO4 to 1 L H2O 
Cryopreservation medium: DMEM; 10 % DMSO 
DMEM / 10 %FCS: DMEM; 10 % FCS; 1 % Pen Strep 
2.2.2 Flow cytometry 
Flow cytometry (FC) buffer: 3 % FCS in PBS 
Antibody solutions: 1:50 in 50 µL FC buffer 
Propidium iodide staining solution: 1 µg/ mL propidium iodide (PI) in FC buffer 
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2.2.3 Membrane assay 
Homogenization buffer: 0.2 mL 1M MOPS (pH 7.0), 0.2 mL 1M KCl, 0.2 mL, 100x 
Complete™ Protease Inhibitor 
Assay buffer: 300 µL 0.5 M sodium nitrate, 10 µL 100x complete, 0.5 µL 20 mM ZnCl2 
in 689.5 µL H2O 
100x complete: 1 complete protease inhibitor tablet in 500 µL H2O 
Whole cell lysis buffer: 2 complete protease inhibitor tablets, 1% triton-X100 in10 mL PBS 
2.2.4 SDS-PAGE and Western Blot (WB) 
Whole cell lysis buffer (2x): 2 complete protease inhibitor tablets, 1% triton-X100 in 50 mL 
PBS 
Laemmli buffer (5x): 62.5 mM Tris pH 6.8, 2% SDS; 10% glycerol, 5% β-mercaptoethanol, 
0.001% bromophenol blue 
Stacking gel (4%): 13.3 mL 30% acrylamide, 16.6 mL 2 M Tris pH 6.8, 0.663 mL 0.5 M 
EDTA, 69.44 mL H2O 
Resolving gel (15%): 50 mL 30% acrylamide, 16,6 mL 2 M Tris pH 8.9, 0.663 mL 0.5 M 
EDTA, 32.74 mL H2O 
Running buffer SDS-PAGE: 150 g Tris, 720 g glycine, 50 g SDS to 5L H2O 
WB washing buffer: 10 tablets PBS, 5 mL Tween-20 to 5L H2O 
1M Tris Buffer: 121.14 g of Tris base in 800 mL H2O 
2.3 Antibodies 
2.3.1 Primary antibodies 
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2.3.2 Secondary antibodies 
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2.4 Oligonucleotides 
2.4.1 qRT-PCR primer 
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2.4.2 Plasmids 
 
2.5 Software 
 
2.6 Cell line 
The wild type cell line E14TG2 was isolated from a mouse blastocyst and kindly 
provided by Markus Conrad (Helmholtz center Munich) and additionally purchased from 
American Type Culture Collection (ATCC, Manassas, USA). All other cell lines were 
established by former members of our lab. 
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3. METHODS 
3.1 Cell culture 
3.1.1 Cell culture conditions 
The passage of mouse embryonic stem cells E14TG2, Bruce4, and all other cell culture 
work was done under a sterile workbench, using sterile tips and solutions. 
Cultivation of cells was carried out by default in an incubator at a temperature of 37 °C, a 
CO2 content of 5%, and at 95% humidity. 
3.1.2 Freezing and thawing of cells 
Cells were harvested by trypsin treatment and were pelleted at RT for five minutes at 300 
g. Subsequently, the cells were dissolved in 1 mL of cold cryopreservation medium, 
transferred to cryogenic vessels, and slowly frozen at -80 °C before being stored in liquid 
nitrogen until further use. 
After rapid thawing of the cells at 37 °C, DMSO in the cryopreservation medium was diluted 
by the addition of five volumes of culture medium. The cell pellet obtained by centrifugation 
(300 g, 5 min.) was then resuspended in fresh medium. After 24 hours, dead cells present 
in the supernatant were removed by renewing the medium. 
3.1.3 Cultivation of cells 
For the cultivation of mouse ESCs E14TG2 and Bruce4, cell culture flasks were coated 
with 0.1% gelatin and subsequently dried 30 minutes under the cell culture workbench. 
ESCs were cultured in the presence of LIF at a concentration of 0.1 unit /1 mL to maintain 
the pluripotency of the cells (Smith et al., 1988). mF9 and HEK293 cells were plated in cell 
culture flasks with DMEM medium containing 20% and 10% FCS respectively. 
At 70% confluency, cells were first washed with phosphate-buffer saline solution (PBS) 
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and then incubated in a 0.5% trypsin solution for five minutes at 37 °C, in order to detach 
cells from the cell culture surface. After stopping the reaction with FCS-containing medium, 
cells were centrifuged (300 g, 5 min), resuspended in an appropriate volume of culture 
medium, and seeded into new cell culture flasks. ESCs were passaged every 48 hours, 
mF9 and HEK293 cells were passaged every 72 hours. 
3.1.4 Cell counting 
To determine cell numbers, cells were harvested following trypsin-treatment as described 
under point 3.1.3. The, 10 μL of the single cell suspension was mixed with trypan blue in 
a 1:1 ratio and counted using a Neubauer chamber (Thermo Fisher Scientific, Waltham, 
USA) under a microscope. Trypan blue allows to distinguish dead cells from living cells.  
Cells / mL = (cells counted/ number of counted large squares) * 104. 
3.1.5 In vitro differentiation of ESCs in embryoid bodies (EBs) 
ESCs can be differentiated using the 3D-differentiation hanging drop method (Wang and 
Yang, 2008). First, ESCs were washed with PBS, harvested by treatment with trypsin, and 
placed in single cell suspension with differentiation medium (i.e. lacking LIF). 
Subsequently, the total number of cells was determined using trypan blue and a Fuchs-
Rosenthal chamber. The cell suspension was diluted to a final concentration of 500 cells 
for spontaneous differentiation in embryoid bodies (EBs) or 1000 cells for 
immunohistochemical experiments, each in a volume of 20 μL. 
After loading the bottom of a cell culture dish (diameter 20 cm) with 20 mL of PBS, the cell 
suspension was applied to the lid of the same cell culture dish in drops with a volume of 
20 μL using a multichannel pipette. Then, the lid was gently rotated and placed on the dish. 
After 72 hours at 37 °C, drops containing EBs were transferred to ultra-low attachment 96-
well plates containing 160 μL fresh differentiation medium, and were incubated for further 
96 hours. Depending on the further procedure, EBs were either maintained in ultra-low 
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attachment plates or transferred into gelatin-coated, standard 96-well flat bottom plates. 
3.1.6 Transfection of ESCs by nucleofection 
ESCs were harvested and counted as described in paragraphs 3.1.3 - 3.1.4. For each 
transfection, 2x106 cells were centrifuged (300 g, 5 min), resuspended in 100 μL Amaxa 
Nuclei transfection reagent, and added to plasmid DNA in the Nuclei transfection solution 
(Lonza Cologne AG, Cologne, Germany). ESCs transfection was then carried out in a 
Nucleofector® (Lonza Cologne AG, Cologne, Germany) using the program A-24 according 
to the manufacturer's instructions. 
3.1.7 Generation of stable cell lines 
To generate stable cell lines, ESCs were transfected as described in paragraph 3.1.6. 24h 
after transfection, puromycin at a concentration of 1 μg / 1 μL was added to the cell medium 
to select for resistant cells. Cells were cultivated for several weeks in the presence of 
puromycin and subsequently analyzed by flow cytometry, western blot, and/or qRT-PCR 
to ensure the expression of the transfected mRNA and protein in the selected cell 
population. 
3.2 Flow cytometry 
To determine the expression of proteins on the cell surface, the method of flow cytometry 
was applied. For this purpose, primary antibodies that bind the extracellular domain of a 
protein were used in combination with fluorescein isothiocyanate (FITC)-conjugated 
secondary antibodies. All antibodies were used in a 1:50 dilution. 
The cells to be examined were washed with PBS, detached from culture plates through 
treatment with trypsin, and harvested in cell culture medium. Subsequently, the cell pellet 
was washed again in PBS, were resuspended in FACS buffer, and were treated with the 
primary antibody for 15 minutes at room temperature (RT). As a control for unspecific 
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binding of secondary antibodies, primary antibodies were omitted. Before staining with 
secondary antibody for 15 minutes, cells were centrifuged and supernatants removed. 
After repeated centrifugation, the pellet was resuspended in 500 μL FACS buffer. 
Furthermore, 0.5 mg / mL of propidium iodide (PI) was added to the cell suspension to 
distinguish between dead and living cells in the following analysis. The assessment and 
analysis of samples was conducted on a FACScalibur device using the CellQuest™ 
software (Becton, Dickinson and Company, Franklin Lakes, USA). PI-positive cells were 
excluded from the analysis. Expression values represent ratios of mean fluorescence 
intensities of the antigen of interest divided by negative controls. 
3.3 Biochemical methods 
3.3.1 Preparation of whole cell lysates 
Cells were collected, washed once with PBS, and centrifuged for 5 min at 280 g and RT. 
The supernatant was discarded and the cell pellet was resuspended in a two-fold volume 
of 2x whole cell lysis buffer. Alternatively, pellets were frozen at -80 °C for several days 
before lysis. After lysis, samples were centrifuged for 10 min at 16000 g and 4 °C to collect 
supernatants which will be transferred into a new tube. BCA-assay will be performed to 
determine the protein concentration. Laemmli buffer was mixed with samples, and then 
heated at 95 °C for 5 min before separation on SDS-PAGE. Protein samples were stored 
at -20 °C. 
3.3.2 Determination of protein concentration 
Protein concentrations were detected by using the BCA assay kit. 5 µL of the protein 
samples were mixed with 100 µL BCA solution and the absorbance at 595 nm wavelength 
was measured with a spectrophotometer (GeneQuantPro, GE Healthcare, Chicago, USA). 
All measurements were performed in triplicates.  
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3.3.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is to separate proteins by mass. As a result, proteins with a smaller molecular 
weight migrate faster than those with a higher molecular weight. Per gel, 10 mL resolving 
gel (15%) were mixed with 50 µL APS and 30 µL TEMED. After polymerization, 2 mL of 
the stacking gel was mixed with 30 µL APS and 15 µL TEMED, poured, and polymerized 
on top of the separation gel additionally using a comb to generate loading pockets. 
Subsequently, same amounts of proteins of whole cell lysate samples were loaded on gels. 
Gel electrophoresis was conducted for 15 min at 15 mA and 2 h at 30 mA in SDS running 
buffer. Afterwards, gels were used for immunoblotting. 
3.3.4 Immunoblotting (Western blot) 
A wet blotting system (BioRad, Hercules, USA) was used in our study. With this system, 
proteins separated in a polyacrylamide gel will be transferred to a polyvinylidene fluoride 
(PVDF) membrane. To do so, membranes were first incubated in methanol for 1 min and 
then transferred into blotting buffer. Blotting was conducted for 50 min at 100 V and RT. 
After blotting, PVDF membranes were firstly incubated in blocking solution for minimally 
30 min at RT. Membranes were washed in washing buffer for 5 min and incubated in 
primary antibody for 1 h at RT or over-night at 4 °C. Subsequently, membranes were 
washed three times in PBST for 5 min and incubated with the secondary antibody for 30 
min at RT. Antigen-antibody reactions were shown via the chemiluminescent HRP 
substrate (Millipore, Burlington, Massachusetts, USA). Images were acquired by a 
ChemiDoc XRS+ imaging system (BioRad, Hercules, USA) and analyzed by ImageLab 
software. 
3.3.5 Immunoprecipitation 
Lysates from cell culture were prepared as described in 3.3.1. Vortex GFP-Trap® A beads 
(ChromoTek GmbH, Munich, Germany) and pipette 25 µl bead slurry into 500 µl ice-cold 
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dilution buffer. Centrifuge at 2500 g for 2 min at 4 °C. Discard supernatant and repeat wash 
twice in cold PBS. Add cell lysate to equilibrated GFP-Trap® A beads, gently rotate for 1 
hour at 4 °C. Centrifuge at 2500 g for 2 min at 4 °C and discard remaining supernatant. 
Resuspend beads in 500 µL ice-cold dilution buffer. Centrifuge at 2500 g for 2 min at 4 °C 
and discard supernatant, repeat this wash twice. Resuspend beads in 100 µL 2x SDS-
sample buffer and boil for 10 min at 95°C to dissociate immunocomplexes from GFP-Trap® 
A beads. Beads can be collected by centrifugation at 2500 g while supernatant containing 
the target proteins can be further performed with the SDS-PAGE. 
3.4 Molecular methods 
3.4.1 RNA concentration measurement 
The concentration of RNA was determined with a Nano drop device (Implen GmbH, 
Munich, Germany). To determine the concentration of nucleic acids in solution, the 
absorbance as measured at the wavelength of 260 nm is used. The ratios of 260 nm /280 
nm and 260 nm /230 nm are calculated for an indication of the purity of the samples. Pure 
RNA samples have expected 260/280 ratios of more than 2.0. 
3.4.2 Isolation of RNA and synthesis of cDNA 
The total RNA isolation of cells was performed with the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. For this purpose, 1x106 cells were 
harvested, washed with PBS, and digested in a corresponding buffer with QiaShredder 
columns. Complementary DNA (cDNA) reverse transcription was performed with the 
QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany) as described below. To 
avoid degradation of total RNA, all pipetting steps were performed on ice according to the 
manufacturer's recommendations. By default, 1 μg of total RNA was reverse transcribed 
using the two-step protocol from Instruction manual of QuantiTect Reverse Transcription 
kit. After digestion of residual genomic DNA in the first step by using DNase, the treated 
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RNA was reverse transcribed to cDNA in the second step. This reaction was terminated 
by inactivation of the reverse transcriptase at 95 °C for 1 min. A small volume of RNA from 
the first step was used as a negative control in the following quantitative polymerase chain 
reaction (qPCR) to exclude RNA contamination with genomic DNA. 
3.4.3 Real Time Quantitative Polymerase Chain Reaction (qPCR) 
For the analysis of gene expression by qPCR, the plate cycler LightCycler® 480 and the 
double-strand-specific master mix LightCycler® 480 SYBR Green I Master (Roche, Basel, 
Switzerland) were used. The sample was prepared according to the following table: 
The reaction mixture and the protocol are summarized in the following table: 
The cycle threshold (CT) value is a theoretical value indicating the beginning of the 
exponential phase of a PCR reaction. The normalization of the CT values of all genes was 
made with the CT value of the housekeeping gene. 
Calculation was as follows: 
1. Average of Cp-values: Cp = ΣCp/3 
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2. Normalization to a housekeeping gene (HG): ΔCp = Cp (gene) - Cp (HG) 
3. Calculation of relative gene expression levels:  
a) Control group (was set to “1.0”): ΔΔCp(control) = 2-(ΔCp(control) - ΔCp(control)) 
b) Sample group: ΔΔCp(sample) = 2-(ΔCp(sample) - ΔCp(control)) 
3.5 Cell labeling and staining methods 
3.5.1 Immunofluorescence 
Embryoid bodies (EBs) generated as described in paragraph 3.1.5 and cell pellets were 
placed in cryomolds, covered bubble-free with the embedding medium "TissueTek" 
(Science Services GmbH, Munich, Germany), snap-frozen with liquid nitrogen, and stored 
at -20 °C. Using a cryo-microtome, 4μm sections were generated, mounted on Super Frost 
slides (Thermo Fisher Scientific, Waltham, USA), and dried at RT before being stored 
again at -20 °C until further use. 
EBs were washed with PBS for 5 min and fixed with 3.5% paraformaldehyde (PFA) for 10 
min in the dark at 4 °C and 5 min in the dark at RT. EBs were then washed with PBS for 5 
min, permeabilized by 4 °C methanol, and blocked with 200 µL horse serum for 20 min at 
RT. Next, EBs were incubated with the first antibody overnight at 4 °C. After three times 
washing in PBS for 5 min, EBs were incubated with an Alexa 488-linked secondary 
antibody 1 h in the dark at RT. Finally, EBs were covered with ProLong™ Gold Antifade 
Mountant with DAPI (Thermo Fisher Scientific, Waltham, USA) to stain nuclei. 
Cells were grown on glass slides and proliferate to 50% confluence followed by treatment 
with DAPT or -lactone. Cells were washed with PBS for 5 min, fixed in 3% PFA for 10 min 
in the dark at RT, cells were then washed in PBS for 5 min and covered with ProLong™ 
Gold Antifade Mountant with DAPI (Thermo Fisher Scientific, Waltham, USA) to stain 
nuclei (Vector Laboratories, Burlingame, USA). 
Both EBs and cells staining were analyzed using a TCS-SP5 scanning system and the 
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LAS AF software (Leica, Wetzlar, Germany). 
3.5.2 Immunohistochemistry 
Samples were fixed in acetone for 5 min at RT, followed by fixation with 3.5% PFA for 10 
min in the dark at 4 °C and 5 min in the dark at RT. Next, samples were washed twice in 
PBS for 5 min at RT and incubated with horse serum for 20 min at RT. Incubation with first 
antibody was performed for 1 h at RT or over-night at 4 °C. After washing samples with 
PBS and Brij solution (Thermo Fisher Scientific, Waltham, USA), sections were incubated 
with a biotinylated anti-mouse antibody for 30 min at RT, washed again with PBS and Brij 
solution, and subsequently incubated with a peroxidase-labeled avidin–biotin complex. 
Finally, samples were stained with amino-ethylcarbazole (AEC), generating a red-brown 
staining of the antigen/antibody complexes. Counterstaining was achieved with 
hematoxylin (blue). Samples were covered with Kaiser’s glycerol gelatin and images were 
acquired via an Olympus BX43F fluorescence microscope and CellEntry software 
(Olympus, Tokyo, Japan). 
3.5.3 Laser Scanning Confocal Microscopy 
For confocal microscopy analysis, EBs and cells were prepared as descried in 3.5.1. 
Images were acquired with a TCS-SP5 laser scanning system, 63x oil immersion objective, 
in which three major filters at wavelengths 358 nm (DAPI), 488 nm (GFP), and 647 nm 
(red) were used to capture the images. The microscope was initially switched to the laser 
scanning live mode at DAPI filter to locate the cells, then the images from green and red 
channel will be recorded at imaging acquiring mode. After these settings were determined, 
the configuration was saved and used for acquisition and analysis of all images in the study 
from different samples. All images were analyzed by LAS AF software (Leica 
Microsystems; Wetzlar, Germany). 
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3.5.4 Epifluorescence microscopy 
Cells were grown to 50% confluence at 10 cm tissue culture dishes. DAPT was added into 
medium 24 hours before the experiment to block the function of -secretase. After 5 times 
PBS wash, new medium without DAPT was added to cells. Images were acquired with an 
Olympus motorized inverted research microscope IX81 and MMI Cellcut Plus software 
(Molecular Machines & Industries, Eching, Germany). Fluorescence intensity across the 
plasma membrane areas was quantified with Fiji software. 959ms in 200x magnification 
and 1180ms in 400x magnification were set as exposure time respectively. 0.5 dB was set 
as gain value and image background was subtracted from all images before quantification. 
Mean fluorescence values at time- point 0 was set to 100% as a reference, all values from 
subsequent time points were normalized to the reference. 
3.6 Statistical analysis 
Results are presented as mean value ± standard error of the mean (SEM) of ≥ 3 
independent experiments unless indicated otherwise. Significant differences between two 
groups were calculated by a Student’s T-test in Prism (GraphPad Software, San Diego, 
USA). Significant differences of more than two groups were calculated with ANOVA test 
with Bonferroni corrections in Prism. Levels of significance were displayed as *p-value < 
0.05; **p-value < 0.01; ***p-value < 0.001; ****p-value < 0.0001, and referred to control 
group unless depicted otherwise. 
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4. RESULTS 
4.1. EpCAM expression and function in mouse ESCs 
4.1.1 Generation of embryoid bodies in vitro 
ESCs are capable of generating the three germ layers ecto-, meso-, and endoderm in vitro, 
and thereby can help understanding early embryogenesis at the cellular and molecular 
levels (Nishikawa, Jakt and Era, 2007). Here, a hanging-drop 3D-differentiation model was 
used to generate embryoid bodies (EBs) from E14TG2 and Bruce4 ESCs (Figure 5). EBs 
closely mimic embryogenesis in vitro and allow genetic manipulations of the cells of interest. 
The method used herein allows to generate EBs from a defined cell number and with 
reproducible size, in which spontaneous differentiation occurs in vitro.  
Fig. 5: Hanging drop method 
Pluripotent E14TG2 or Bruce4 ESCs were harvested, placed in single cell suspension, and cultured 
using the hanging-drop method (500 cells per drop in 20 µL volume). After three days of incubation, the 
spheroid-like structures termed embryoid bodies (EBs) were transferred to ultra-low attachment multi-
well plates for an additional four days. On day seven, EBs were transferred to gelatin-coated plates, in 
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which they were incubated until the end of each experiment. Wild-type cells were photographed on 
different days with a microscope. While the first picture shows the morphology of cells initially used for 
the generation of EBs, the following two non-adherent EBs are depicted. On day ten, the EBs were 
already attached to the bottom surface of the plate and was further differentiated. Shown are 
representative pictures of the respective culture conditions of the EBs. 
 
Figure 5 shows the exact procedure of the hanging-drop method. A single cell suspension 
consisting of 2.5 * 103 cells / mL in differentiation medium is prepared and 20 µL drops are 
placed on the lid of a 20 cm diameter cell culture dish for three days in an incubator under 
standard conditions. On day three, EBs formed in hanging drops are transferred into ultra-
low attachment multi-well plates, to which EBs do not adhere. EBs will be then incubated 
for additional four days at 37 °C and subsequently transferred into gelatin-coated 96-well 
culture plates to be kept for different durations, depending on the particular experimental 
setup (Figure 5). 
4.1.2 Characterization of early 3D-differentiation of ESCs 
The formation and spontaneous differentiation of EBs from E14TG2 ESCs were already 
evaluated in our lab (Sarrach et al., 2018). In the present study, EBs were generated from 
a second ESC line, namely Bruce4, and were cultured for 10 days in differentiation medium 
lacking LIF. Differentiation of the cells within EBs was verified by staining of the 
pluripotency cell surface marker SSEA-1 (Solter and Knowles, 1978; Williams et al., 1988) 
after disintegration of EBs into single cell suspension (Figure 6A) . Additionally, EpCAM 
on the cell surface was also examined in a pluripotent state and at day 10 of differentiation 
by flow cytometry. 
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Fig. 6: EpCAM and SSEA-1 expression on pluripotent and differentiated Bruce4 ESCs 
(A) EBs were generated from Bruce4 ESCs and were cultured for 10 days in differentiation medium 
lacking LIF. The expression of EpCAM and pluripotency marker SSEA-1 on the surface of ESCs (dark 
grey) and differentiated EBs (light gray) were determined by flow cytometry using EpCAM- and SSEA-
1-specific antibodies. Negative controls are displayed as black lines. Shown are representative 
histograms from n = 3 independent experiments. (B) Shown are the means and standard deviations of 
EpCAM and SSEA-1 expression in pluripotent ESCs and EBs from n = 3 independent experiments. p-
value were calculated with a Two-way ANOVA test and multiple posthoc comparisons with Bonferroni 
correction.  ****<0.0001. 
 
A 
B 
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Figure 6A shows representative histograms of the flow cytometry measurement of the 
membrane proteins EpCAM and SSEA-1. EpCAM is highly expressed in ESCs in the 
pluripotent state, while it is strongly reduced in EBs after 10 days of differentiation (Figure 
6A, top). A similar expression pattern of SSEA-1 was assessed by flow cytometry in the 
same samples (Figure 6A, bottom). Mean cell surface expression levels of EpCAM and 
SSEA-1 were calculated from three independent experiments, and revealed 87% and 86% 
decreases after 10 days of differentiation, respectively (Figure 6B). The reduction of 
SSEA-1 at the protein level confirmed a differentiated state of Bruce4 ESCs after 10 days 
of 3D-differentiation in EBs. Furthermore, a subpopulation of differentiated ESCs retained 
the expression of EpCAM, as visualized by a “shoulder” of EpCAM+ cells in flow cytometry 
histograms (Figure 6A). 
Fig. 7: EpCAM and Oct3/4 expression during differentiation of Bruce4 ESCs 
Bruce4 ESCs were differentiated in EBs for 10 days. Bruce4 ESCs were then harvested on day 0, 5, 
and 10 of differentiation, RNA was isolated, cDNA was synthesized, and the expression of EpCAM and 
Oct3/4 was quantified by quantitative RT-PCR. The values measured in n = 3 independent experiments 
were averaged and presented with the corresponding standard deviations. p-value were calculated with 
a Two-way ANOVA test and multiple posthoc comparisons with Bonferroni correction.  ****<0.0001. 
 
Next, Bruce4 ESCs were cultured for 10 days and harvested on day 0, 5, and 10 of 
differentiation. RNA was isolated at each time point and quantitative RT-PCR (qRT-PCR) 
was performed to evaluate the expression of Oct3/4 at these three time points. The results 
revealed a substantial reduction of the pluripotency marker Oct3/4 at the transcriptional 
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level over the time (Figure 7, grey bar). On day five, expression of Oct3/4 was decreased 
to 44%, while on day 10, it was decreased to 5% of the initial levels of undifferentiated 
Bruce4 ESCs. Similar to the reduction of the pluripotency marker Oct3/4, transcription of 
the EPCAM gene was reduced to 45% on day five and to 15% on day 10, as compared to 
the levels of EPCAM in undifferentiated, pluripotent Bruce4 ESCs (Figure 7, black bar). 
Hence, Bruce4 ESCs could be reproducibly differentiated in EBs, with a loss of SSEA-1, 
Oct3/4, and EpCAM expression that was comparable to levels and kinetics observed in 
E14TG2 ESCs (Sarrach et al., 2018). 
4.1.3 EpCAM patterning in early 3D-differentiation of ESCs 
Heterogeneous down-regulation of EpCAM was observed in previews flow cytometry 
results, with a majority of cells losing the expression and a minor population retaining 
EpCAM. Therefore, in order to further understand the regulation of EpCAM patterning 
during early differentiation of EBs, pluripotent Bruce4 ESCs were plated in hanging drops 
and EBs were harvested at different time points, cryo-sections were generated, and were 
then stained with an EpCAM-specific antibody. 
Fig. 8: EpCAM patterning in early 3D-differentiation of Bruce4 EBs 
Bruce4 ESCs were harvested, washed, and plated in hanging drops and transferred after three days to 
ultra-low attachment plates. From day three on, EBs were shock-frozen, sectioned, and stained with 
EpCAM-specific antibody for the time points of day 3, 4, 5, 6, 8 and 10. Shown are representative 
staining at each time point from n = 3 independent experiments with 18 EBs in each experiment. 
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In differentiating EBs from Bruce4 cells, loss of EpCAM expression and segregation of 
clusters of EpCAM+ and EpCAM− cells occurred from day four to five onwards, and resulted 
in spatiotemporal patterning of EpCAM, eventually resulting in an outer margin area 
composed of EpCAM+ cells, while the majority of cells within the EBs had lost EpCAM 
(Figure 8).  
Fig. 9: Selective expression of EpCAM in differentiated ESCs in EBs 
Bruce4 ESCs were harvested, washed, and plated in hanging drops, and transferred after three days 
to ultra-low attachment plates. Subsequently, the EBs from different time points at day 3, 6, 8, and 10 
were shock-frozen, sectioned, and were stained with EpCAM-specific antibody. Shown are the 
representative staining at each time points from n = 3 independent experiments with 12 EBs in each 
experiment. 
 
Further enlargements in Figure 9 show that EpCAM+ cells were homogeneously 
distributed in EBs at day three of differentiation. At day six of differentiation, a distinct 
patterning of EpCAM expression became obvious. From day eight onwards, a minor 
population of cells with strong EpCAM expression was localized at the margin of the EBs 
and linings of vacuoles. At day 10 of differentiation, the majority of cells revealed EpCAM- 
(Figure 8, 9). Hence, EpCAM displays a spatiotemporally selective expression throughout 
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spontaneous ESCs differentiation. 
4.1.4 EpCAM expression in ecto-, meso-, and endoderm 
During 3D-differentiation of Bruce4 ESCs, a selective loss and maintenance of EpCAM 
expression was observed in EBs. EBs are comprised of three embryonic germ layers, i.e. 
ecto-, meso-, and endoderm (Itskovitz-Eldor et al., 2000). To investigate the correlation 
between the selective expression of EpCAM and the three germ layers in EBs, 
immunohistochemistry (IHC) and immunofluorescence (IF) staining were performed on 
section of EBs by using antibodies specific for each germ layer. 
4.1.4.1 EpCAM expression in endoderm 
Foxa2 is a member of a family of nuclear transcription factors that play a role in cell 
commitment, differentiation, and organ-specific gene transcription. Foxa2 also has an 
important function in the regulation of epithelialization in mouse endoderm (Burtscher and 
Lickert, 2009a). Here, we used Foxa2 as an endoderm-specific marker to study the 
distribution of EpCAM within endodermal cells in differentiated ESCs in EBs. 
Consecutive sections of Bruce4 EBs were stained with EpCAM and Foxa2, respectively, 
at day eight of EBs differentiation. At this time point, patterning of EpCAM is pronounced. 
EpCAM expression partially overlapped with Foxa2 expression. A similar localization of 
EpCAM with Foxa2 was primarily observed in marginal cells in consecutive sections of 
EBs, which could represent cells of the visceral endoderm, and in more central areas of 
EBs (Figure 10A). To further analyze the correlation of EpCAM and Foxa2, 
immunofluorescence double-staining of EpCAM and Foxa2 was performed with 
E14TG2 EBs. In differentiated E14TG2 EBs at day 5, EpCAM and Foxa2 co-localized 
in cells at the edge of EBs. Magnification of fluorescence staining confirmed at the cellular 
level that EpCAM was localized on the cell surface, while Foxa2 was expectedly expressed 
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within cells (Figure 10B). 
Fig. 10: EpCAM and Foxa2 expression in differentiated ESCs 
Bruce4 and E14TG2 ESCs were harvested, washed, and plated in hanging drops, and transferred 
after three days to ultra-low attachment plates. Subsequently, the EBs from day eight of Bruce4 ESCs 
and day five of E14TG2 ESCs were shock-frozen, cryo-sectioned and were stained with EpCAM- and 
Foxa2-specific antibodies. (A) Shown are two representatives immunohistochemistry staining of 
EpCAM and Foxa2 in Bruce4 EBs sections (day eight) rom n = 3 independent experiments. (B) Shown 
are representative immunofluorescence double-staining of EpCAM and Foxa2 in E14TG2 EBs (day 
five) with different magnifications. The images from stained slides of EBs were acquired via a laser 
scanning confocal microscope. Shown are the representative images from n = 3 independent 
experiments with 6 EBs in each experiment. 
 
A 
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4.1.4.2 EpCAM expression and mesoderm 
Vimentin is an intermediate filament protein that is highly expressed in mesenchymal cells 
and is frequently used as a marker for cells derived from the mesoderm, and for cells 
undergoing EMT in normal and malignant differentiation. 
Fig. 11: EpCAM and Vimentin expression in differentiated ESCs 
Bruce4 and E14TG2 ESCs were harvested, washed, and plated in hanging drops, and transferred 
after three days to ultra-low attachment plates. Subsequently, the EBs from day eight of Bruce4 ESCs 
and day five of E14TG2 ESCs were shock-frozen, cryo-sectioned, and were stained with EpCAM- and 
Vimentin-specific antibodies. (A) Shown are representatives immunohistochemistry staining of EpCAM 
and Vimentin in Bruce4 EBs sections (day eight) from n = 3 independent experiments. (B) Shown are 
immunofluorescence double-staining of EpCAM and Vimentin in E14TG2 EBs (day five) with different 
magnifications. The images from stained slides of EBs were acquired via a laser scanning confocal 
microscope. Shown are the representative images from n = 3 independent experiments with 6 EBs in 
each experiment. 
 
Figure11A shows consecutive sections of Bruce4 EBs stained with EpCAM- and Vimentin-
specific antibody on day eight of spontaneous differentiation. A mutually exclusive 
A 
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expression was found in a comparison of the staining of EpCAM and Vimentin in 
consecutive sections of EBs. To confirm this exclusive expression pattern, 
immunofluorescence double-staining of EpCAM and Vimentin was performed with 
E14TG2 EBs on day five (Figure 11B). EpCAM+ cells at the margin of and within EBs 
did not express Vimentin, while, conversely, EpCAM- cells revealed Vimentin+. Hence, 3D-
differentiation of ESCs results in EpCAM+/Vimentin- and EpCAM-/Vimentin+ cell cluster 
segregation in EBs. 
4.1.4.3 EpCAM and ectoderm 
Nestin is an intermediate filament protein whose expression is widely used as a marker for 
stem cells in the developing nervous system and for in vitro cultured ectodermal cells. 
Here, Nestin served as an ectodermal marker to investigate a correlation of the expression 
of EpCAM and ectoderm. 
Fig. 12: EpCAM and Nestin expression in differentiated ESCs 
A 
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Bruce4 and E14TG2 ESCs were harvested, washed, and plated in hanging drops, and transferred 
after three days to ultra-low attachment plates. Subsequently, the EBs from day eight of Bruce4 and 
day five were shock-frozen, cryo-sectioned and were stained with EpCAM- and Nestin-specific 
antibodies. (A) Shown are two representatives immunohistochemistry staining of EpCAM and Nestin in 
Bruce4 EBs sections (day8) from n = 3 independent experiments. (B) Shown are immunofluorescence 
double-staining of EpCAM and Nestin in E14TG2 EBs (day five) with different magnifications. The 
images from stained slides of EBs were acquired via a laser scanning confocal microscope. Shown are 
the representative images from n = 3 independent experiments with 6 EBs in each experiment. 
 
Figure12A shows consecutive sections of Bruce4 EBs stained with EpCAM- and Nestin-
specific antibodies on day eight of spontaneous differentiation in EBs. No obvious 
correlation of expression could be observed between EpCAM and Nestin in consecutive 
EBs sections. To confirm this, immunofluorescence double-staining of EpCAM and Nestin 
was performed with E14TG2 EBs on day five of spontaneous differentiation in EBs. 
EpCAM expression was unrelated to Nestin, suggesting that the distribution of EpCAM is 
not correlated with ectodermal cells (Figure 12B). 
Taken together, it can be concluded that EBs generated by the hanging drop method are 
an adequate 3D model to simulate early embryonic development in vitro, as EBs are 
comprised of all three germ layers. Secondly, EpCAM is generally down-regulated in the 
majority of differentiated cells within EBs following spontaneous differentiation. However, 
endodermal cells maintain the expression of EpCAM, especially within marginal cells 
representing Foxa2+ visceral endoderm, whereas Vimentin+ mesodermal cells are entirely 
devoid of EpCAM. 
4.1.5 Function of EpCAM in ESCs differentiation 
During early gastrulation, the expression of EpCAM demonstrated to be selective in space 
and time. Endodermal cells retained a strong expression of EpCAM, whereas EpCAM 
becomes entirely down-regulated in mesodermal progenitors. Based on our previews data, 
it was known that EpCAM over-expression inhibited mesodermal differentiation to 
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cardiomyocytes (Sarrach et al., 2018), but that, however, mesodermal differentiation 
depended on EpCAM+ endodermal cells. These results were achieved with the use of 
CRIPR-Cas 9-dependent knockout variants of EpCAM in E14TG2 ESCs. A requirement 
of physical contact between EpCAM+ Sox17-producing endodermal cells and mesodermal 
cells has been described in earlier publications (Holtzinger, Rosenfeld and Evans, 2010; 
Varner and Taber, 2012). 
In this respect, the heart develops from mesoderm early in embryonic differentiation. 
Cardiac progenitors locate in the lateral plate mesoderm and maintain close contact with 
the underlying endoderm. Accordingly, co-culture of mouse ESCs with endodermal cell 
lines resulted in a strong induction of Flk1+/PDGFR+ cardiac progenitors in a dose-
dependent fashion (Uosaki et al., 2012). These results suggested that EpCAM+ 
endodermal cells are mandatory for the formation of cardiomyocytes during development, 
however, the actual impact of a loss-of-function of EpCAM still remains largely unknown. 
4.1.5.1 Characterization of CRISPR/Cas9-mediated EpCAM knockout ESCs clones 
To understand embryonic development in the absence of EpCAM, knockout E14TG2 
clones were generated by CRISPR-Cas9-mediated genetic engineering with EpCAM-
specific guide RNAs, and were confirmed via genomic DNA sequencing and protein 
expression. All EpCAM knockouts in ESCs used in experiments performed in the present 
thesis were homozygous clones. 
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Fig. 13: Characterization of EpCAM knockout E14TG2 ESCs clones 
E14TG2 wildtype (WT) and EpCAM single knockout clones #56, #58, #62, #114, #118, and #138 
ESCs were cultured in gelatin-coated flasks, and images were acquired every week. (A) Shown are 
EpCAM knockout clones #56, #58, #62, #114, #118, and #138 ESCs maintained under pluripotency 
conditions in the presence of LIF. (B) E14TG2 WT and EpCAM knockout clones ESCs were collected, 
RNA was isolated, and EpCAM mRNA levels were assessed via qPCR. Shown are the mean values 
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with standard deviations from n = 3 independent experiments. p-value were calculated with a One-way 
ANOVA test with multiple posthoc testing and Bonferroni correction. ****<0.0001. (C) Whole cell extracts 
of E14TG2 WT and EpCAM knockout clones ESCs were generated, proteins were separated via SDS-
PAGE and detected with EpCAM-specific antibody. Staining of GAPDH served as loading control for 
equal protein amounts. Shown are representative immunoblot results from n = 3 independent 
experiments. 
 
E14TG2 WT and EpCAM knockout clones (#56, #58, #62, #114, #118, #138) were used 
in this study. All cell lines were cultured under pluripotent conditions in the presence of LIF. 
Images of the morphology of each ESC clone were acquired weekly, and their typical 
round-shaped colonies were visualized via microscopy. Figure 13A shows a typical ESC 
morphology of all knockout clones (#56, #58, #62, #114, #118, #138). EpCAM mRNA and 
protein levels were assessed in WT and EpCAM-knockout ESC clones using quantitative 
RT-PCR and immunoblot staining. EpCAM knockout clones displayed severally reduced 
EpCAM mRNA levels (Figure 13B, C). Residual mRNA levels of EPCAM following 
CRISPR/Cas9 knockout may result from non-homologous end-joining of double-strand 
breaks. Despite these residual mRNA levels, protein expression was entirely lost in all n = 
6 EpCAM knockout ESCs clones. 
#2 #9 #16 A 
B C 
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Fig. 14: Characterization of CRISPR/Cas9 control E14TG2 ESCs clones 
E14TG2 WT and control clones #2, #9, #16 were compared. CRIPSR/Cas9 knockout control clones 
#2, #9, and #16 represent single cell clones of E14TG2 ESCs that have been transfected with guide 
RNA and Cas9, but did not show any obvious differences in EpCAM expression compared to WT 
E14TG2 ESCs. All cell lines were plated in gelatin-coated flasks and images were acquired every 
week. (A) Shown are n = 3 CRISPR/Cas9 control clones that were regularly maintained under 
pluripotency conditions in the presence of LIF. Images are shown from representative colonies. (B) 
Whole cell extracts of E14TG2 WT and control clones #2, #9, and #16 ESCs were collected, proteins 
were separated in SDS-PAGE, and EpCAM was detected with specific antibody. Staining of GAPDH 
served as loading for equal protein amounts. Shown are representative immunoblot results from n = 3 
independent experiments. (C) E14TG2 WT and control clones (#2, #9, #16) ESCs were collected, 
washed and determined by flow cytometry using EpCAM-specific antibody. Shown are mean 
fluorescence intensity ratio (MFI-R) with standard deviations from n = 3 independent experiments. p-
value were calculated with a One-way ANOVA test with multiple posthoc testing and Bonferroni 
correction. *<0.05; ns>0.05. 
 
Apart from n = 6 EpCAM knockout clones, three additional clones (#2, #9, #16) were 
selected as controls. These controls were generated through transfection of the 
CRISPR/Cas9 all-in-one plasmid containing an expression cassette for Cas9, an EpCAM-
specific guide-RNA, and GFP as a marker for FACS-based selection of transfected cells. 
Single cell clones were generated and three clones, which did not show any apparent 
differences in EpCAM expression compared to WT E14TG2 ESCs, were further 
analyzed. The morphology of each cell clones was recorded under pluripotency conditions 
in the presence of LIF in the culture medium. All three CRISPR/Cas9 control clones 
showed a typical stem cell colony morphology (Figure 14A). The presence of EpCAM 
protein at the cell surface and in cell lysates was assessed by flow cytometry and 
immunoblot, respectively. Flow cytometry results showed single cell E14TG2 clone #9 
has 40% less EpCAM expression compared to WT E14TG2 with statistical difference 
(Figure 14B), while the two remaining control clones exhibit a comparable expression level 
of EpCAM. Similar to flow cytometry data, immunoblot results displayed a clear expression 
of EpCAM protein at 35 kDa, which was reduced in single cell E14TG2 clone #9 (Figure 
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14C). The results suggested that two out of three control clones expressed comparable 
level of EpCAM of WT E14TG2 ESCs, while clone #9 displayed approx. halved levels of 
EpCAM. 
Fig. 15: Expression of the pluripotency markers Oct3/4 and Nanog in WT E14TG2 and 
CRISPR/Cas9 control clones 
E14TG2 WT, CRIPSR/Ca9 EpCAM-knockout clones #56, #58, #62, #114, #118, #138 and 
CRIPSR/Cas9 control clones #2, #9, #16 were plated in gelatin-coated flask under pluripotency 
conditions in the presence LIF. RNA was isolated from cells and qPCR was performed to detect Oct3/4 
and Nanog mRNA expression levels as pluripotency markers. (A) Shown are E14TG2 WT and EpCAM 
knockout clones. (B) Shown are E14TG2 WT and CRISPR/Cas9 control clones. The expression levels 
of Oct3/4 and Nanog mRNA were normalized for the expression in E14TG2 WT cells. Results are 
presented as means with standard deviations from n = 3 independent experiments. p-value were 
calculated with a Two-way ANOVA test with multiple posthoc testing and Bonferroni correction. *<0.05; 
**<0.01; ns>0.05. 
 
A 
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Next, the pluripotency of E14TG2 WT and knockout clones was evaluated in all single 
cell clones under pluripotency conditions, i.e. in the presence of LIF in the culture media. 
E14TG2 EpCAM knockout clones were characterized by reduced expression of 
pluripotent genes Oct3/4 and Nanog, ranging from 20%–48% and 57%–75% reduction, 
respectively (Figure 15A), confirming that EpCAM was involved in the maintenance of 
stem cell pluripotency. Three CRISPR/Cas9 control clones displayed levels of Oct3/4 and 
Nanog mRNA comparable to ET14TG2 WT cells, thus suggesting full pluripotency of 
these control clones. 
4.1.5.2 Differentiation of ET14TG2 WT cells and CRISPR/Cas9 derivatives 
Upon spontaneous differentiation in EBs, ET14TG2 WT cells generate contracting 
cardiomyocytes in vitro. Thus, the differentiation of ET14TG2 WT cells and CRISPR/Cas9 
derivatives was monitored regarding the formation of cardiomyocytes (EBs contracting 
ratio) and the size of EBs. None of the EpCAM+ CRISPR/Cas9 control clones was impaired 
in cardiomyocyte development, as measured through the rates of contracting EBs and 
compared to ET14TG2 WT cells (Figure 16A). In contrast, four out of six EpCAM 
knockout clones were severely impaired in the formation of contracting EBs, with 
contraction rates dropping to 0.1–12.5% (Figure 16B). These data demonstrated that the 
genetic knockout of EpCAM had a negative impact on the spontaneous differentiation of 
ET14TG2 WT cells into contracting cardiomyocytes in EBs. 
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Fig. 16: Differentiation of ET14TG2 WT cells and CRISPR/Cas9 derivatives into contracting 
cardiomyocytes 
E14TG2 WT and CRISPR/Cas9 EpCAM knockout cell lines were harvested, washed, and plated in 
hanging drops, and transferred after three days to ultra-low attachment plates. On day seven, EBs were 
transferred to 96-well plate with fresh medium. On day 10 of the differentiation of EBs, the percentage 
of contracting EBs was recorded and normalized to the numbers of total EBs. (A) Shown are the mean 
percentages with standard deviations of contracting EBs of E14TG2 WT and CRISPR/Cas9 control 
clones from n = 3 independent experiments with n≥80 EBs in each experiment. (B) Shown are the mean 
percentages with standard deviations of contracting EBs of E14TG2 WT and CRISPR/Cas9 EpCAM 
knockout cell lines from n = 3 independent experiments with n ≥ 80 EBs in each experiment. p-value 
were calculated with a One-way ANOVA test with multiple posthoc testing and Bonferroni correction. 
****<0.0001; ns>0.05. 
 
4.1.5.3 Impact of EB size on spontaneous differentiation of ESCs 
During the generation of EBs, E14TG2 WT and EpCAM knockout clones were 
characterized by differences in EBs size. EpCAM knockout clones revealed significantly 
smaller than WT EBs at day five of differentiation (Figure 17A). It has been reported that 
the size of EBs plays a role in the efficiency of cardiomyocyte formation (Hwang et al., 
2009). Therefore, the potential impact of differing EBs sizes on the formation of 
B A 
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cardiomyocytes was evaluated with E14TG2 WT and EpCAM knockout clones. 
Fig. 17: Correlation of ESCs numbers with EBs size in vitro 
E14TG2 WT ESCs and CRISPR/Cas9 EpCAM knockout clones #56, #114 were harvested, washed, 
and plated in hanging drops with different initial number of 50, 500 and 5,000 cells, respectively. EBs 
were transferred to ultra-low attachment plates after three days. On day seven, EBs were transferred 
A 
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again to 96-well plate with fresh medium. (A) On day five of the differentiation of ESCs in EBs, images 
of representative EBs were acquired via microscopy. (B) From these microscopic images, diameters 
were measured and volumes of EBs were extrapolated. Shown are mean volumes with standard 
deviations from n = 3 independent experiments with n = 27 EBs in each experiment. p-value were 
calculated with a One-way ANOVA test with multiple posthoc testing and Bonferroni correction. 
****<0.0001; ns>0.05. 
 
Different initial number of cells of E14TG2 WT and EpCAM knockout clones #56 and 
#114 (50, 500, and 5,000) were plated in 96-well plates to generate EBs. Representative 
pictures of EBs at day five including diameters are depicted in Figure 17A. Volume 
extrapolation of EBs was performed with three independent biological repeats, and mean 
and SD are presented in Figure 17B. Generally, E14TG2 WT ESCs generated EBs of 
bigger size compared with both CRISPR/Cas9 EpCAM knockout clones at equal starting 
cell numbers (Figure 17B). A tenfold excess of CRISPR/Cas9 EpCAM knockout clones 
#56 and #114 (5,000 cells) was required to generate EBs of equal size to E14TG2 WT 
cells (500 cells) (Figure 17B), suggesting that the knockout of EpCAM in ESCs impacted 
on the capacity of cells to proliferate during differentiation in EBs. 
Fig. 18: Correlation of EBs size with cardiomyocyte formation in vitro 
E14TG2 WT ESCs and CRISPR/Cas9 EpCAM knockout clones #56, #114 were harvested, washed, 
and plated in hanging drops with different initial cell numbers of 50, 500, and 5,000 cells, respectively. 
EBs were transferred after three days to ultra-low attachment plates. On day seven, EBs were 
transferred again to 96-well plate with fresh medium. On day 10 of the differentiation of EBs, the 
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percentage of contracting EBs were recorded and normalized to the numbers of total EBs. Shown are 
the mean percentages with standard deviations of contracting EBs from n = 3 independent experiments 
with n = 27 EBs in each experiment. p-value were calculated with a One-way ANOVA test with multiple 
posthoc testing and Bonferroni correction. ****<0.0001. 
 
In a following experiment, the contraction rate of EBs from E14TG2 WT and EpCAM 
knockout clones #56 and #114 with starting cell numbers of 50, 500, and 5,000 cells was 
assessed in a 10 days differentiation. The aim of this experiment was to assess whether 
equivalent EBs size can rescue the cardiomyocyte formation defect of EpCAM knockout 
clones. Although EBs generated from CRISPR/Cas9 EpCAM knockout clones could reach 
a size equivalent to E14TG2 WT EBs at a tenfold cell excess, neither EpCAM knockout 
clone #56 nor #114 was able to generate functional cardiomyocytes (Figure 18). While 
E14TG2 WT EBs required a starting cell number of 500 to display high percentages of 
contracting EBs, EpCAM knockout clones #56 and #114 were incapable of differentiating 
to contracting cardiomyocytes, even at starting seeding number of 5,000 cells (Figure 18). 
4.1.5.4 Mesp1 is important for cardiomyocyte differentiation 
Cardiogenesis is a complex process that is organized and orchestrated by multiple genes. 
Mesoderm posterior protein 1 (Mesp1) acts as a master regulator in cardiomyocyte 
formation. Genome-wide measurements of RNA revealed Mesp1 is able to activate and 
inhibit cardiac-associated genes. Chromatin immunoprecipitation data proved Mesp1 can 
directly bind to the promoter of many key genes associated with the cardiac transcriptional 
machinery, to upregulate their expression (Bondue et al., 2008). Throughout 
cardiomyocyte formation, mesodermal progenitors initially require a Mesp1/Wnt5a-
dependent activation, which is then followed by a reduction of Wnt5a and Mesp1, and 
finally the induction of Wnt11 expression in order to complete cardiomyocyte maturation 
via the physical contact and instruction with Sox17+/EpCAM+ endodermal cells (Hwang et 
al., 2009; Holtzinger, Rosenfeld and Evans, 2010; Mazzotta et al., 2016a). 
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Fig. 19: Analysis of the transcriptional expression dynamics of cardiomyocyte markers during 
E14TG2 differentiation 
E14TG2 WT ESCs were harvested, washed, and plated in hanging drops, and differentiated for 10 
days. EBs were collected at each time points of day 0, 3, 5, 7, 10, RNA of EBs was isolated, and EpCAM 
(A), Mesp1, Wnt5a (B), Gata4, Nkx2.5 (C) and -CAA, Wnt11 (D) expression on transcriptional level 
were measured by qRT-PCR. Values at different time points are normalized to the highest value in each 
group. Shown are the means and standard deviations of EpCAM and cardiomyocyte markers 
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expression during EBs differentiation from n = 3 independent experiments. p-value were calculated with 
a One-way ANOVA test with multiple posthoc testing and Bonferroni correction. *<0.05; ****<0.0001. 
 
Spontaneous differentiation of E14TG2 WT cells was performed in a kinetic experiment 
over 10 days, and expression of EpCAM and various genes was measured by qRT-PCR. 
Here, Wnt5a, Mesp1 as early regulators, Gata4, Nkx2.5 as intermediate regulators, Wnt11 
as a late regulator, and -CAA as a marker for matured cardiomyocyte were assessed. 
The assessment of mRNA levels of these genes showed a time dependency, with a peak 
of Wnt5a, Mesp1 (Figure 19B), and Gata4 mRNA expression at day five (Figure 19C), 
and a strong or complete loss of Wnt5a and Mesp1 (Figure 19B) at day seven, 
respectively. Gata4 was decreased to 48% at day 10 (Figure 19C). Starting from day five, 
Wnt11, Nkx2.5, and -CAA expression was gradually increased and peaked at day 10 
(Figure 19C, D). 
Fig. 20: Kinetic expression of the mRNA of cardiogenesis-associated genes during E14TG2 WT 
ESCs differentiation in EBs 
Summary of the results of the kinetics of cardiogenesis-associated genes. E14TG2 WT ESCs were 
harvested, washed, and plated in hanging drops, and differentiated for 10 days. EBs were collected at 
each time points of day 0, 3, 5, 7, 10, RNA of EBs was isolated, EpCAM, Mesp1, Wnt5a, Gata4, Nkx2.5, 
-CAA, and Wnt11 expression at the transcriptional level were measured by qRT-PCR. Shown are the 
mean values of the expression of EpCAM and cardiomyocyte markers at the transcriptional level during 
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EBs differentiation from n = 3 independent experiments. Values at different time points are normalized 
to the highest value in each group. EpCAM, Mesp1, Wnt5a, gata4, nkx2.5, Wnt11 and Nkx2.5 are 
presented as black, blue, red, purple, cyan, orange and grey curve, respectively. 
 
Taken together, Mesp1 appears to be required as a master regulator to induce Gata4 and 
Nkx2.5 expression at early stage of ESCs differentiation into cardiomyocytes. At later 
stages, the expression of Mesp1 and wnt5a has to be down-regulated, and expression of 
wnt11 induced, to allow differentiating ESCs to fully mature -CAA+ cardiomyocytes 
(Figure 20). 
4.1.5.5 EpCAM knockout impacts on cardiomyocyte differentiation 
Fig. 21: EpCAM knockout impacts on the expression of genes related to cardiomyocyte 
differentiation 
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E14TG2 WT ESCs and CRISPR/Cas9 EpCAM knockout clones #56, #58, #62, #114, #118, and #138 
were harvested, washed, and plated in hanging drops, and transferred after three days to ultra-low 
attachment plates. On day seven, EBs were transferred to 96-well plate with fresh medium. RNA was 
isolated from EBs on day 10, and the expression of the mRNA of the cardiomyocyte differentiation-
associated genes Mesp1, Wnt5a, Gata4, Nkx2.5, Wnt11, and a-CAA was assessed by qRT-PCR. 
Shown are the means and standard deviations as relative mRNA expression levels of n = 3 independent 
experiments with n = 27 EBs in each experiment. All values were normalized to the value of E14TG2 
WT ESCs in each experiment. p-value were calculated with a One-way ANOVA test with multiple 
posthoc testing and Bonferroni correction. *<0.05; **<0.01; ***<0.001; ****<0.0001. 
 
To understand the dysfunction of cardiomyocyte formation in non-contraction EBs derived 
from CRISPR/Cas9 EpCAM knockout clones, the abovementioned cardiomyocytes genes 
were assessed at day 10 in E14TG2 WT and CRISPR/Cas9 EpCAM knockout clones 
#56, #58, #62, #114, #118, and #138. 
Unlike E14TG2 WT and EpCAM knockout clones that generated contracting EBs (i.e. 
#58 and #118), EpCAM knockout clones #56, #62, #114, and #138 did not efficiently 
downregulate Mesp1 expression, and eventually expressed 10- to 20-fold higher Mesp1 
mRNA levels compared to E14TG2 WT on day 10 (Figure 21). Accordingly, slightly 
increased levels of Wnt5a were measured in these non-contracting E14TG2 clones, too, 
and genes associated with cardiomyocyte differentiation including Gata4, Nkx2.5, Wnt11, 
and -CAA were significantly reduced compared to WT EBs at day 10 of spontaneous 
differentiation (Figure 21). 
Taken together, the differentiation of EBs of non-contracting E14TG2 EpCAM knockout 
clones was blocked at a Mesp1+ stage. As depicted in Figure 20, Mesp1 displays a 
biphasic expression pattern characterized by the induction of its expression around day 
three of differentiation with a peak of expression at day five. Throughout further 
differentiation, Mesp1 expression is down-regulated, while Wnt11, Nkx2.5, and -CAA 
become up-regulate at day 10. However, non-contracting clones maintained high levels of 
expression of Mesp1 and, though much less pronounced, of wnt5a expression at day 10. 
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These data indicate that the differentiation of EpCAM knockout EBs was blocked at a 
Mesp1+ stage (Figure 20). 
4.1.6 EpCAM regulates ESCs differentiation via the ERas/AKT cascade 
From previews data obtained in our research group, it was known that EpCAM cleavage 
products EpCTF and EpICD, which are generated through regulated intramembrane 
proteolysis, do not inhibit cardiomyocyte formation. Constitutive expression of either 
EpCTF or EpICD in E14TG2 did not impair cardiomyocyte formation, suggesting an 
inhibitory function for full-length EpCAM. Furthermore, although a knockout of the EPCAM 
gene impaired the cardiomyocyte formation, two out six clones remained capable of 
generating functional cardiomyocyte. In order to understand the mechanism behind these 
somewhat conflicting results, potential binding partners and down-stream signaling of 
EpCAM were further investigated. 
4.1.6.1 Characterization of ERas as an EpCAM-binding partner 
To assess the interacting partners of full-length EpCAM, stable isotope labeling with amino 
acids in cell culture (SILAC), immunoprecipitation and liquid chromatography–mass 
spectrometry (LC-MS/MS) were performed by Matthias Hachmeister (Ph.D. student in our 
group). A total of 77 candidates for EpCAM-interaction partners were identified through a 
combination of SILAC and LC-MS/MS with the mouse teratocarcinoma cell line mF9. 
Prohibitin 1/ 2 represented top ranking interaction candidates, while Calnexin and ERas 
represented potential candidates with inferior enrichment scores. 
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Next, interactions of EpCAM with prohibitin 1 and 2, calnexin, and ERas were validated in 
lysates of E14TG2 cells expressing either EpCAM fused to the yellow fluorescent protein 
(EpCAM-YFP) or YFP as a control.  
Fig. 22: Characterization of the interaction of EpCAM with Prohibitin 1 and 2, Calnexin, and ERas 
in E14TG2 ESCs 
E14TG2 ESCs stably expressing EpCAM-YFP or YFP were cultured under pluripotency conditions in 
the presence of LIF, cells were harvested, and cell lysates were used for co-immunoprecipitation 
experiments. EpCAM-YFP and YFP proteins were enriched with GFP-trap beads and were separated 
on SDS-PAGE. The co-precipitation of (A) prohibitin 1 and 2, and (B) calnexin and ERas were assessed 
with specific antibodies upon immunoblotting. Equal expression of prohibitin 1 and 2, calnexin, and 
ERas in both E14TG2 derivative cell lines were confirmed by immunoblotting of whole cell lysates. 
Comparable immunoprecipitation of EpCAM-YFP and YFP was assessed in immunoblotting with GFP-
B 
A 
 65 
 
specific antibody (recognizing YFP). Shown are representative immunoblots from n = 3 independent 
experiments. 
 
Figure 22 shows co- immunoprecipitation results of prohibitin1/2, calnexin, and ERas. All 
four proteins were co-precipitated together with EpCAM-YFP, but not with the control YFP 
(Figure 22). Amongst these four candidates, ERas appeared particularly interesting 
because of its association to ESCs. Distinctively from Prohibitins 1 and 2, and Calnexin, 
embryonic stem cell-expressed RAS (ERas), which encodes a Ras-like GTPase protein, 
was initially characterized as an ESCs-associated molecule that is involved in the 
tumorigenicity of mouse ESCs (Takahashi, Mitsui and Yamanaka, 2003). Through binding 
to phosphatidylinositol 3 kinase (PI3K) and phosphorylation of AKT, ERas promotes the 
growth of ESCs and activates an ERas–AKT–FOXO1 signalling pathway during somatic 
cell reprogramming (Takahashi, Mitsui and Yamanaka, 2003; Yu et al., 2014). Hence, 
these data suggested a role for ERas in cell proliferation during early mouse embryonic 
development (Rodriguez-Viciana et al., 1994; Bedzhov et al., 2014). These aspects 
qualified ERas as an interesting interaction partner of EpCAM that might explain the 
cellular effects of EpCAM in ESCs. 
4.1.6.2 Function of EpCAM/ERas/Akt signaling in ESCs 
The stable expression of exogenous EpCAM in E14TG2 ESCs induced an increase in 
AKT phosphorylation at serine473 and a hyper-activation of AKT under insulin-like growth 
factor treatment (Sarrach et al., 2018). In opposite, knockout of EpCAM in ESCs reduced 
the activating phosphorylation of AKT by 72.5% in average, and reduced ERas expression 
was observed concurrently (Sarrach et al., 2018), suggesting a novel EpCAM/ERas/pAKT 
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signaling cascade in ESCs. 
Fig. 23: Function of the EpCAM/ERas/Akt signaling in the differentiation of ESCs into 
cardiomyocytes 
E14TG2 WT ESCs and stable pCAG (control cell line), Flag-ERas, and myrAKT1 transfectants of 
E14TG2 ESCs were cultured under pluripotency conditions in the presence of LIF. (A, B) Cells were 
harvested and cell lysates (30ug) were used for immunoblotting with ERas- and pAKT-specific 
antibodies. (C) EBs were generated from E14TG2 WT ESCs and stable pCAG (control cell line), Flag-
ERas, and myrAKT1 transfectants of E14TG2 ESCs, and were spontaneously differentiated until day 
10. The percentage of contraction of EBs were recorded and normalized to 100%. Shown are mean 
and standard deviations of n = 3 independent experiments. p-value were calculated with a One-way 
ANOVA test with multiple posthoc testing and Bonferroni correction. ****<0.0001. 
 
To address the function of ERas/Akt signaling in cardiomyocyte formation, a FLAG-tagged 
 67 
 
version of ERas and a myristoylated, hyperactive variant of AKT (myrAKT) were stably 
transfected into E14TG2 ESCs (Figure 23A, B). Ectopic expression of Flag-ERas and 
myrAKT reduced the contraction rate of EBs by 35% and 40% respectively (Figure 23C), 
suggesting that the over-expression of ERas impairs cardiomyocyte formation via 
ERas/Akt signaling. 
Taken all results above, EpCAM expression is tightly regulated during differentiation of 
ESCs in order to achieve a mandatory spatiotemporal cellular heterogeneity of EpCAM in 
endo- and mesodermal lineages. Four out of six ESCs EpCAM- single clones only partially 
developed through the mesodermal differentiation and progress was blocked at a Mesp1+ 
stage, ultimately leading to a dysfunction of the formation of contracting cardiomyocytes. 
Potential binding partners and down-stream signaling of EpCAM were further investigated 
to understand the retained contracting capacity of the remaining two clones. SILAC and 
Co-IP experiments both identify a binding partner ERas which play a role in ESCs 
differentiation. The two EpCAM- contracting clones display a further impairment of 
cardiomyocyte formation after ERas knockout, suggesting a complementary function of 
ERas to cardiomyocyte formation. In addition, loss of EpCAM in ESCs reduce both ERas 
and phosphorylated AKT expression, suggesting a novel EpCAM/ERas/pAKT signaling 
pathway. 
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4.2 Timing of EpCAM regulation by RIP 
The differential regulation of EpCAM expression during stem cell differentiation was 
described in section 4.1 of this study. ESCs downregulate the expression of EpCAM 
starting from day 5.0 of spontaneous differentiation at the mRNA level, while EpCAM 
protein at the cell membrane was already entirely lost in selected cells at an earlier time 
point of 3.5-4.0 days (Sarrach et al., 2018). Based on a half-life of EpCAM of 21 h 
determined in human carcinoma cells, the combination of all data suggested an additional 
post-translational regulation of EpCAM expression during ESCs differentiation. To the best 
of our current knowledge, cells have two major post-translational mechanisms to down-
regulate EpCAM from the cell membrane, which are cleavage by RIP and endocytosis. 
Therefore, the timing of EpCAM regulation by RIP was addressed experimentally in this 
study. 
4.2.1 Establishment of an EpCTF-YFP cell model to study the pace of 
intramembrane proteolysis of EpCAM 
EpCAM is cleaved by BACE1 or ADAM10/17 in the extracellular domain to release the 
ectodomain EpEX. The resulting C-terminal fragment (EpCTF) is a substrate that is 
recognized and further cleaved by the -secretase complex. This generates an A-like 
fragment and an intracellular domain EpICD in succession (Figure 24A). With the aim of 
investigating the efficiency and speed of EpCTF cleavage by -secretase, i.e. the second 
cleavage of EpCAM in the process of RIP, the mouse and human variants of the EpCTF 
that contain the signal peptide, a c-Myc tag, 35 membrane-proximal amino acids (aa) of 
extracellular domain, and the transmembrane and intracellular domains of EpCAM were 
fused to the yellow fluorescence protein (YFP), as shown in Figure 24B. The resulting 
EpCTF-YFP molecules (mEpCTF-YFP and hEpCTF-YFP) represent each a mimic of 
mouse and human EpCTF that allow for the evaluation of the proteolysis of EpCTF by -
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secretase in living cells through the detection of YFP fluorescence. 
 
C 
D 
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Fig. 24: Generation of mouse and human EpCTF variants 
(A), Scheme of RIP of EpCAM through ADAM10/17, BACE1, and -secretase with the releasing 
fragments (EpEX: EpCAM extracellular domain; EpICD: EpCAM intracellular domain; EpCTF: EpCAM 
C-terminal fragment). (B), EpCTF-YFP variants include the signal peptide of mouse or human EpCAM 
(1–23), a short linker peptide, which contains 2 amino acids (KL), the CTF fragment of mouse EpCAM 
(251–315) and human EpCAM (250–314), as well as the yellow fluorescence protein (YFP). (C), 
Immunoblotting served to analyze EpCTF-YFP and EpICD-YFP expression with antibody specific to 
YFP in stable mF9 mEpCTF-YFP transfectants and in stable HEK293 hEpCTF-YFP transfectants. In 
order to visualize EpCTF-YFP and EpICD-YFP each transfectants was treated as indicated with -
secretase inhibitor DAPT or proteasome inhibitor -lactone (-lac.). The staining of -actin helped to 
verify equal protein loading. Shown are representative results of n = 3 independent experiments. (D), 
Quantification of immunoblotting results in C was obtained from n = 3 independent experiments. Shown 
are mean values with standard deviations. One-way ANOVA with multiple posthoc testing and 
Bonferroni correction served to calculate the p-value. (E), mF9 and HEK293 cells with mouse and 
human EpCTF-YFP, respectively, were treated as indicated with DMSO, -lactone, or DAPT. YFP 
fluorescence signal was monitored by laser scanning confocal microscopy. mF9 and HEK293 cells 
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expressing a YFP-tagged human or mouse full-length EpCAM or YFP served as controls. Shown are 
the representative results of n = 3 independent experiments. 
 
In order to confirm the correct cleavage and degradation of EpCTF-YFP and EpICD-YFP 
through -secretase and the proteasome, respectively, immunoblotting of whole cell 
lysates of stable transfectants of mouse EpCTF-YFP in mouse F9 teratoma cells and of 
human EpCTF-YFP in human embryonic kidney (HEK293) cells was performed. The -
secretase inhibitor DAPT was applied to treat both cell lines in order to block EpCTF-YFP 
cleavage, while the proteasome inhibitor -lactone was applied to block the following 
degradation of EpICD. Control-treated mF9 and HEK293 transfectants expressed only low 
levels of mouse and human EpICD-YFP and EpCTF-YFP fragments, respectively (Figure 
24C). After treatment with DAPT for 24 h, EpCTF-YFP was detected as a minor band of 
42kDa together with a dominant band of 45kDa, while EpICD was not or only faintly 
detected (Figure 24C). -lactone treatment was performed for 12 h to inhibit the 
proteasome and resulted in the accumulation of both mouse and human EpICD-YFP as 
32kDa protein (Figure 24C). Three independents immunoblot experiments were 
implemented to quantify the expression levels of mouse and human EpCTF and EpICD. 
By using -secretase inhibitor DAPT to treat cells to stabilize mEpCTF and hEpCTF, both 
EpCTFs exhibited a 23-fold increased expression compared with control cells treated with 
DMSO (Figure 24D). By using the proteasome inhibitor -lactone, mEpICD and hEpICD 
showed a 20-fold and 25-fold increase compared with DAPT-treated cells, respectively 
(Figure 24D). From these experiments, it can be concluded that mouse and human 
EpCTF-YFP proteins are processed by -secretase, and that the resulting EpICD 
fragments become degraded via the proteasome. 
Laser scanning confocal microscopy was then applied to evaluate the correct sub-cellular 
localization of the EpCTF-YFP fusions. DAPT, DMSO, or -lactone was used to treat mF9 
and HEK293 with mouse and human EpCTF-YFP. After treatment with DMSO, YFP 
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signals at the plasma membrane could barely be detected, and perinuclear staining and 
intracellular aggregates were faint (Figure 24E). In cells treated with DAPT, mouse and 
human EpCTF-YFP were readily observed at the plasma membrane. After incubating with 
-lactone without DAPT, mouse and human EpICD-YFP exhibited a homogeneous 
accumulation in the cytoplasm (Figure 24E). The control cell lines, which expressed 
mouse and human full-length EpCAM fused to YFP (EpCAM-YFP), exhibited the expected 
localization at the plasma membrane. As a further control, YFP-expressing cells displayed 
an evenly distributed signal throughout the cell (Figure 24E). 
To sum up, mouse and human EpCTF-YFP variants were expressed in mF9 and HEK293 
cells, respectively, and displayed a correct localization and response to the inhibitors 
compared with endogenous EpCTF (Maetzel et al., 2009). 
4.2.2 Biochemical evaluation of the cleavage of EpCTF via -secretase 
In order to calculate the protein turnover of EpCTF (half-life: 50% turnover) by -secretase 
and to quantify the degradation efficiency of EpICD by the proteasome, time course 
experiments were carried out in combination with a detection of EpCTF-YFP and 
proteolytic products by immunoblotting. 
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Fig. 25: Biochemical assessment of mouse and human EpCTF-YFP cleavage 
(A), Mouse F9 teratoma cells stably expressing mEpCTF-YFP were treated with DAPT for 12 h. 
Thereafter, cells were either maintained in medium containing DAPT (DAPT maintenance), or were 
washed and maintained in normal medium (DAPT withdrawal), or were washed and subsequently 
maintained in medium containing -lactone over a total time period of 5 h (-lactone). Whole cell lysates 
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of cells at the indicated time points of treatment were analyzed by immunoblotting with GFP-specific 
antibody, which detects YFP equally well. mEpCTF-YFP and mEpICD-YFP were detected. Shown are 
representative results of n = 3 independent experiments. (B), Expression of mEplCD-YFP and mEpCTF-
YFP was quantified, and mEpCTF 50% protein turnover was calculated based on the n = 3 independent 
experiments. Shown are the mean values with standard deviations. One-way ANOVA with multiple 
posthoc testing and Bonferroni correction served to calculate p-value. **<0.01; ***<0.001; ****<0.0001. 
(C), Human HEK293 cells stably expressing hEpCTF-YFP were treated with DAPT for 12 h. Thereafter, 
cells were either maintained in medium containing DAPT (DAPT maintenance), or were washed and 
maintained in normal medium (DAPT withdrawal), or were washed and subsequently maintained in 
medium containing -lactone over a total time period of 5 h (-lactone). Whole cell lysates at the 
indicated time points of treatment were analyzed by immunoblotting with GFP-specific antibody, which 
detects YFP equally well. hEpCTF-YFP and hEpICD-YFP were detected. Shown are representative 
results of n = 3 independent experiments. (D), Expression of hEpICD-YFP and hEpCTF-YFP was 
quantified, and hEpCTF 50% protein turnover was calculated based on n = 3 independent experiments. 
Shown are the mean values with standard deviations. One-way ANOVA with multiple posthoc testing 
and Bonferroni correction served to calculate the p-value. **<0.01; ***<0.001; ****<0.0001. 
 
mF9 and HEK293 transfectants expressing mEpCTF-YFP and hEpCTF-YFP, respectively, 
were treated with DAPT for 12 h in order to inhibit CTF cleavage by -secretase. Following 
this treatment, cells were either maintained in the presence of DAPT in the cell culture 
medium, or were washed and cultured in standard medium without DAPT, or, as a third 
variant, were washed and cultured in the presence of the proteasome inhibitor -lactone. 
These three different treatments were conducted over a period of 5 h or 24 h for mF9 and 
HEK293 cells, respectively. Cell samples were collected at different time points. mEpICD-
YFP and mEpCTF-YFP expression levels were assessed after 0, 10, 30, 60, 120, 180, and 
300 min. In the continuous presence of DAPT, mEpCTF-YFP expression levels was not 
significantly changed over the observation time period of five h 5 h (Figure 25A and B, left 
panels). Withdrawal of DAPT resulted in mEpCTF-YFP cleavage with a calculated 50% 
reduction of protein expression at 47 ± 12 min (Figure 25A and B, middle panels). After 
additional treatment with -lactone, quantification of immunoblots for mEpICD-YFP and 
mEpCTF-YFP showed that mEpICD-YFP accumulation reached 50% of EpCTF-YFP 
levels after 70 min (Figure 25A and B, right panels). 
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Cleavage of human EpCTF-YFP and proteasomal degradation of human EpICD-YFP was 
assessed in stable HEK293 transfectants following the same procedure. No obvious 
changes could be seen in the expression levels of hEpCTF-YFP after 24 h maintenance 
in culture medium supplied with DAPT (Figure 25C and D, left panels). Following the 
withdrawal of DAPT, hEpCTF-YFP was cleaved by -secretase with a calculated 50% 
reduction after 3.5 ± 0.8 h (Figure 25C and D, middle panel). Inhibition of the proteasome 
with -lactone disclosed a 50% stabilization of hEpICD-YFP after 3.5 h in average (Figure 
25C and D, right panels).  
 
A 
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Fig. 26: Mouse EpCTF-YFP cleavage in mouse NIH3T3 fibroblast cells 
(A), Mouse EpCTF-YFP was stably expressed in NIH3T3 fibroblasts. Stable transfectants were then 
treated with -secretase inhibitor DAPT for 24 h and then cells were cultured in medium without DAPT 
for another 24 h. Immunofluorescence microscopy was applied to monitor YFP fluorescence at the 
indicated time points. Shown are the representative pictures from n = 3 independent experiments at 
400x and 200x magnification. (B), Quantification of immunofluorescence microscopy results shown in 
A was carried out from a total of n = 30 cells from n = 3 independent experiments. Shown are the mean 
values with standard deviations. One-way ANOVA with multiple posthoc testing and Bonferroni 
correction served to calculate p-value. ****<0.0001. (C), Expression of mEpCTF-YFP was visualized by 
immunoblotting in whole cell lysates of NIH3T3 fibroblasts stably transfected with mEpCTF-YFP using 
GFP-specific antibody. Similar loading of each sample was confirmed by staining with -actin-specific 
antibody. Shown are representative results from n = 3 independent experiments. (D), Quantification of 
the protein turnover of mEpCTF (50% protein remaining) was calculated based on the n = 3 independent 
immunoblot experiments. Shown are the mean values with standard deviations. One-way ANOVA with 
multiple posthoc testing and Bonferroni correction served to calculate p-value. **<0.01; ***<0.001; 
****<0.0001. 
 
With a time of 47 ± 12 min and 3.5 ± 0.8 h required to catalyze 50% of the protein amount 
of mEpCTF-YFP and hEpCTF-YFP by -secretase, respectively, this process of enzymatic 
cleavage is very slow. In order to confirm that the abovementioned values are not specific 
to the cell type initially used, mEpCTF-YFP and hEpCTF-YFP were expressed in mouse 
NIHT3T3 fibroblasts and in the squamous cell carcinoma line FaDu, respectively. 
Based on a 24 h observation period by epifluorescence microscopy, the fluorescence of 
mEpCTF-YFP was gradually reduced in NIH3T3 cells (Figure 26A). The fluorescence 
intensity was quantified over time in n = 10 cells of n = 3 independent experiments (n = 30 
total cells), and the average half-life of mEpCTF-YFP was calculated as 5.0 h (Figure 
C D 
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26B). The mEpCTF-YFP cleavage over time was confirmed though biochemical analysis 
of whole cell lysates of mEpCTF-YFP-expressing NIH3T3 fibroblasts at identical time 
points (Figure 26C). mEpCTF-YFP showed a 50% protein turnover rate of 5.3 ± 1.1 h in 
the NIH3T3 cells, as determined by the immunoblot quantification (Figure 26D). Hence, 
cleavage of mEpCTF-YFP by -secretase is a slow process, independently of the cell line 
used. 
Fig. 27: Human EpCTF cleavage in human FaDu carcinoma cells 
A 
B 
C D 
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(A), Human EpCTF-YFP was stably expressed in FaDu carcinoma cells. Stable transfectants were 
treated with -secretase inhibitor DAPT for 24 h and then cells were maintained in culture medium 
without DAPT for another 24 h. Immunofluorescence microscopy was applied to monitor YFP 
fluorescence at the indicated time points. Shown are the representative pictures from n = 3 independent 
experiments at 400x and 200x magnification. (B), Quantification of immunofluorescence microscopy 
results shown in A was carried out from a total of n = 30 cells in n = 3 independent experiments. Shown 
are the mean values with standard deviations. One-way ANOVA with multiple posthoc testing and 
Bonferroni correction served to calculate p-value. ****<0.0001. (C), Expression of hEpCTF-YFP was 
visualized by immunoblotting in whole cell lysates of FaDu cells stably transfected with hEpCTF-YFP 
using GFP-specific antibody. Similar loading of each sample was confirmed by staining with -actin-
specific antibody. Shown are representative results from n = 3 independent experiments. (D), 
Quantification of the protein turnover of hEpCTF (50% protein remaining) was calculated based on n = 
3 independent immunoblot experiments. Shown are the mean values with standard deviations. One-
way ANOVA with multiple posthoc testing and Bonferroni correction served to calculate p-value. 
**<0.01; ***<0.001; ****<0.0001. 
 
Similar results were obtained with respect to the cleavage of human EpCTF-YFP upon 
stable transfection in FaDu cells. After assessing the fluorescence of YFP, an average half-
life of 4.7 h was calculated (Figure 27A-B). According to the biochemical evaluation of 
hEpCTF-YFP cleavage, hEpCTF-YFP exhibited a protein turnover of 50% at 5.1 ± 1.1 h 
(Figure 27C-D). Hence, cleavage of EpCTF-YFP by -secretase is a slow process, 
independently of the cell line used and irrespective of the species of origin of EpCAM. 
4.2.3 The pace of proteolysis of EpCTF is dictated by -secretase 
Despite of the generally very slow proteolysis of mEpCTF and hEpCTF, there was an 
obvious difference in the 50% protein turnover rates of the EpCTFs in all tested cell lines 
(minimum: 45 min; maximum: 5.3 h in mF9 cells and HEK293 cells, respectively). 
 79 
 
 
Fig. 28: hEpCTF cleavage in mouse F9 teratoma cells 
(A), Human EpCTF-YFP was stably expressed in mouse F9 teratoma cells. Stable transfectants were 
treated with -secretase inhibitor DAPT for 24 h and then cells were cultured in medium without DAPT 
for another 5 h. Immunofluorescence microscopy was applied to monitor YFP fluorescence at the 
A 
B 
C 
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indicated time points. Shown are the representative pictures from n = 3 independent experiments at 
400x and 200x magnification. (B), Quantification of immunofluorescence microscopy results shown in 
A was carried out from a total of n = 30 cells in n = 3 independent experiments. Shown are the mean 
values with standard deviations. One-way ANOVA with multiple posthoc testing and Bonferroni 
correction served to calculate p-value. ****<0.0001. (C), Expression of hEpCTF-YFP was visualized by 
immunoblotting in whole cell lysates of mF9 cells stably transfected with hEpCTF-YFP using GFP-
specific antibody. Similar loading of each sample was confirmed by staining with -actin-specific 
antibody. Shown are representative results from n = 3 independent experiments. (D), Quantification of 
the protein turnover of hEpCTF (50% protein remaining) was calculated based on n = 3 independent 
immunoblot experiments. Shown are the mean values with standard deviations. One-way ANOVA with 
multiple posthoc testing and Bonferroni correction served to calculate p-value. **<0.01; ***<0.001; 
****<0.0001. (D), The difference between the half-life of hEpCTF and mEpCTF at each time point of 
analysis in mF9 cells was calculated with a Two-way ANOVA with multiple posthoc testing and 
Bonferroni correction. The test showed an overall p-value of 0.96 with individual p-value in the range of 
0.88-0.99. 
 
In order to define the rate-limiting elements during the EpCTF cleavage, we implemented 
cross-species swapping experiments, where mEpCTF and hEpCTF-YFP -YFP were 
expressed in HEK293 and mouse F9 cells, respectively. Epifluorescence microscopy 
served to record the cleavage of hEpCTF-YFP in mF9 cells, and demonstrated that YFP 
fluorescence decreased in a time frame of 30 to 60 min following DAPT withdrawal (Figure 
28A). Quantification of the fluorescence of YFP over time in n = 10 cells of the n = 3 
independent experiments (n = 30 total cells), the average half-life period was calculated 
as 53.07 min (Figure 28B). Based on the immunoblot analysis of hEpCTF-YFP in mouse 
F9 cells, the cleavage rate detected via fluorescence imaging could be confirmed. The 
protein turnover reached 50% at 45 ± 2.3 min (Figure 28C). On that account, according to 
microscopy as well as immunoblotting experiments, the cleavage rate of human and 
mouse EpCTF-YFP was very similar in mF9 cells, and 50% of hEpCTF-YFP molecules 
underwent cleavage at approx. 45 min in mF9 cells as compared to 3.5 h in HEK293 cells. 
These similar rates of cleavage were corroborated by statistical analysis with a Two-way 
ANOVA of each time point between hEpCTF and mEpCTF in mF9 cells. With an overall p-
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value of 0.96, the cleavage rate of human and mouse EpCTF did not differ (Figure 28D). 
Fig. 29: mEpCTF cleavage in human HEK293 cells 
(A), Mouse EpCTF-YFP was stably expressed in human HEK293 cells. Stable transfectants were then 
treated with -secretase inhibitor DAPT for 24 h and then cells were cultured in medium without DAPT 
for another 24 h. Immunofluorescence microscopy was applied to monitor YFP fluorescence at the 
A 
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indicated time points. Shown are the representative pictures from n = 3 independent experiments at 
200x and 400x magnification. (B), Quantification of immunofluorescence microscopy results shown in 
A was carried out from n = 30 cells in n = 3 independent experiments. Shown are the mean values with 
standard deviations. One-way ANOVA with multiple posthoc testing and Bonferroni correction served 
to calculate p-value. ****<0.0001. (C), Expression of mEpCTF-YFP was visualized by immunoblotting 
in whole cell lysates of mF9 cells stably transfected with mEpCTF-YFP using GFP-specific antibody. 
Similar loading of each sample was confirmed by staining with -actin-specific antibody. Shown are 
representative results from n = 3 independent experiments. (D), Quantification of the protein turnover 
of mEpCTF (50% protein remaining) was calculated based on n = 3 independent immunoblot 
experiments. Shown are the mean values with standard deviations. One-way ANOVA with multiple 
posthoc testing and Bonferroni correction served to calculate p-value. **<0.01; ***<0.001; ****<0.0001. 
(D), The difference between the half-life of hEpCTF and mEpCTF at each time point of analysis in mF9 
cells was calculated with a Two-way ANOVA with multiple posthoc testing and Bonferroni correction. 
The test showed an overall p-value of 0.10 with individual p-value in the range of 0.34-0.99. 
 
Similarly, epifluorescence microscopy in combination with immunoblotting was used to 
analyze the cleavage pace of mEpCTF-YFP in HEK293 cells. Both assays confirmed that 
mEpCTF-YFP protein expression was reduced over 24 h and the calculated average 50% 
protein turnover was 3.31 h, according to the fluorescence intensity kinetics of a total of n 
= 30 cells (Figure 29A-B). Evaluation of the biochemical assessment of the half-life of 
mEpCTF-YFP in HEK293 cells confirmed a 50% reduction after 3.3 ± 1.2 h (Figure 29C). 
No statistical difference was detected between mEpCTF and hEpCTF in terms of their 
cleavage pace in HEK293 cells. Two-way ANOVA displayed an overall p-value at 0.10 and 
individual p-value changed in the range of 0.34 and 0.99 at the different time points of 
analysis (Figure 29D). Therefore, cross-species swapping experiments illustrated the 
association between the cleavage pace of EpCTF variants and endogenous -secretase 
activity, rather than the species of origin of the substrate EpCTF. 
4.2.4 Molecular basis for the observed similarity in cleavage pace of EpCTFs from 
different species 
The cleavage rate of mouse and human EpCTF variants was determined by -secretase, 
rather than EpCTF itself. Therefore, amino acid (aa) sequences of mEpCTF and hEpCTF 
 83 
 
were analyzed regarding their identity, functional similarity, as well as differences in a 
protein stretch from aa 230-315 of mEpCTF and 229-314 of hEpCTF. mEpCTF and 
hEpCTF showed a functional identity of 91% in the abovementioned aa stretch, and 
functional identity reached 95% in reported -secretase cleavage sites and 96% in 
transmembrane domains (Hachmeister et al., 2013; Tsaktanis et al., 2015) (Figure 30). 
EpCTF exhibited identical -secretase cleavage sites between mEpCTF and hEpCTF, with 
exception of the 4 site, which differed from a threonine to an arginine, respectively (Figure 
30). Hence, EpCTF variants share a high degree of conservation across mouse and human 
species, particularly in -secretase cleavage sites. Therefore, we conclude that the 
cleavage pace is dependent on the -secretase complex rather than the CTF substrate. 
Fig. 30: Similarities in amino acid sequences of EpCTF variants 
Comparison of the aligned amino acid (aa) sequences of mouse and human EpCTF. AA in red font 
mark differences between mouse and human EpCTF variants. AA in green font mark residues with 
different aa, but with functional equivalence. mEpCTF and hEpCTF showed a functional identity of 91%, 
demonstrating that their amino acid sequences were highly conserved. The -secretase cleavage sites 
and transmembrane domains showed a functional identity of 95% and 96%, respectively. Most  and  
cleavage site of the EpCTF variants were identical with the exception of the 4 site.  
 
4.2.5 Assessment of endogenous EpCTF cleavage pace 
In the next experiments, we aimed to validate the findings on the slow cleavage rate of 
 84 
 
EpCTF-YFP variants for endogenous EpCTF cleavage in membrane fractions of 
carcinoma cells. DAPT was used to treat the head and neck squamous carcinoma cell line 
FaDu and the ileocecal adenocarcinoma cell line HCT8 for 24 h, in order to block cleavage 
of endogenous EpCTF by -secretase. Following withdrawal of DAPT, the kinetics of 
EpCTF cleavage was assessed in immunoblot experiments.  
Fig. 31: Assessment of endogenous EpCTF cleavage 
Assessment of endogenous EpCTF cleavage in FaDu and HCT8 cells. FaDu and HCT8 cells were 
maintained with the -secretase inhibitor DAPT for 24 h and then cells were cultured in medium without 
DAPT for another 24 h. Subsequently, the expression of endogenous EpCTF was monitored with 
EpICD-specific antibody. Shown are the representative results of n = 3 independent immunoblot 
experiments (left panels), as well as the mean values of EpCTF expression intensities with standard 
deviations (right panels). One-way ANOVA with multiple posthoc testing and Bonferroni correction 
served to calculate p-value. **<0.01; ***<0.001; ****<0.0001. 
 
DAPT treatment of HCT8 and FaDu cells resulted in the accumulation of endogenous 
human EpCTF fragment, which was subject to a slow cleavage after withdrawal of DAPT 
(Figure 31, left panels). Quantification of immunoblot results disclosed a half-live of 
endogenous EpCTF of 4.7 ± 0.7 h in FaDu cells and of 5.5 ± 2.7 h in HCT8 cells (Figure 
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31, right panels). Therefore, it was confirmed that the cleavage process of endogenous 
human EpCTF via -secretase was slow in the carcinoma cells, too. 
4.2.6 EpICD degradation by the proteasome shows high efficiency 
Following cleavage of EpCTF by -secretase, EpICD is released into the cytoplasm and 
can translocate into the nucleus (Maetzel et al., 2009; Chaves-Pérez et al., 2013). 
Generally, EpICD exhibited a low stability and only a small fraction of it was detected in 
nucleus (Maetzel et al., 2009; Pan et al., 2018), where EpICD deploys its functions as a 
signaling active moiety (Maetzel et al., 2009; Lu et al., 2010; H. P. Huang et al., 2011; 
Denzel et al., 2012; Lin et al., 2012; Yu, Ma and Wang, 2017). In order to control functions 
of EpICD, cells require modalities of degradation, which are commonly assumed by the 
proteasome. With the aim to quantify the proteasomal degradation efficiency of human and 
mouse EpICD, the ratios of EpICD to EpCTF were calculated from western blots of cells 
treated with and without -lactone. 
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Fig. 32: Degradation efficiency of EpICD 
Immunoblotting results from 4.2.2 served to calculate the ratios of EpICD-YFP and EpCTF-YFP in order 
to quantify the degradation efficiency of EpICD. Differences between EpICD/EpCTF ratios in the 
absence and presence of the proteasome inhibitor -lactone represent the percentage of degradation 
of mEplCD and hEpICD variants in the top and bottom panel, respectively. Shown are mean values 
with standard deviations of each n = 3 independent experiments. Calculated percentages of degradation 
over time are given in the in-lay table. 
 
In mF9 cells treated with -lactone in the absence of DAPT, the EpICD/EpCTF ratio 
exhibited a gradual increase from 0.02 to 22.88, demonstrating the accumulation of 
mEpICD. In the absence of -lactone and following the withdrawal of DAPT, the 
EpICD/EpCTF ratio presented an initial increase to 0.83 and a subsequent decrease to 
0.29, suggesting a sequential accumulation of mEpICD followed by a degradation by the 
proteasome (Figure 32, left panel). The differences in ratios between two groups of 
treatment represented the percentages of mEpICD degradation by the proteasome. Five 
hours after withdrawal of DAPT, the degradation of mEpICD reached 99% in the absence 
of -lactone (Figure 32, left panel). Similarly, the degradation of hEpICD reached 94% 
after 24 h of withdrawal of DAPT in HEK293 cells (Figure 32, right panel). Thus, the 
proteasome can degrade mouse and human EpICD fragments in an efficient manner, 
which occurs after cleavage of EpCTF by -secretase. 
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5. DISCUSSION 
The differentiation of pluripotent ESCs into mature cells of the adult organism, which 
assume a huge diversity of functions, is a highly complex process that is orchestrated by 
numerous regulatory molecules. These molecules are comprised of cell surface receptors, 
intracellular mediators, transcription factors, and effector molecules. One cell surface 
protein that is highly expressed in pluripotent ESCs is the epithelial cell adhesion molecule 
EpCAM. Throughout ESCs differentiation, EpCAM is characterized by a spatiotemporal 
regulation, which eventually results in a programmed differential expression in mature 
cells. Accordingly, in adult organisms EpCAM is primarily found in epithelial cells, and 
lacking in all other cells. 
In the present study, this spatiotemporal regulation of EpCAM in ESCs was analyzed in-
depth and functional consequences were addressed. 
5.1 EpCAM is required for full differentiation of pluripotent ESCs 
Pluripotent ESCs express high levels of EpCAM, whereas cellular levels of EpCAM differ 
substantially during early differentiation of ESCs (González et al., 2009; Sarrach et al., 
2018). Here, clusters of EpCAM+ and EpCAM- differentiating ESCs were interspersed after 
3.5-4 days of spontaneous differentiation of E14TG2 ESCs in EBs. Consecutive single 
staining and double-staining demonstrated that EpCAM was co-expressed with Foxa2. 
Foxa2 is a transcription factor typically expressed in visceral endodermal and endodermal 
cell clusters in embryos at a later stage of differentiation (Burtscher and Lickert, 2009b). 
Similarly, the formation of visceral endoderm at the outer rim of EBs has been confirmed 
during the early differentiation of ESCs (Liu et al., 2009). In the present study, co-
localization of EpCAM with Foxa2 was frequently observed in marginal cells of EBs, 
suggesting an expression of EpCAM in nascent visceral endoderm. 
Vimentin, an intermediate filament protein expressed in mesodermal cells, displayed a 
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mutually exclusive expression pattern with EpCAM in EBs. Generally, vimentin+ cells were 
entirely devoid of EpCAM, which supported the notion that differentiation of mesodermal 
cells required a strict loss of EpCAM (Sarrach et al., 2018). This assumption was further 
corroborated at the functional level via a forced retention of EpCAM in ESCs through 
exogeneous expression. Overexpression of EpCAM from the strong cytomegalovirus 
promoter negatively impacted on mesodermal differentiation into cardiomyocytes (Sarrach 
et al., 2018). However, a genetic knockout of the EPCAM gene using the CRISPR/Cas9 
technology in E14TG2 ESCs resulted in inhibitory effects on cardiomyocytes 
differentiation too, i.e. a substantial reduction or loss of EBs contraction upon spontaneous 
differentiation of EpCAM knockout ESCs. Generally, guided differentiation of EpCAM 
knockout single cell clones further demonstrated a reduced pluripotency of these cells, 
which is in accordance with reported functions of EpCAM in human and mouse ESCs, as 
well as in porcine induced pluripotent stem cells (iPS) (González et al., 2009; Lu et al., 
2010; Ng et al., 2010; Yu, Ma and Wang, 2017). Based on EpCAM knockout and 
overexpressing ESCs clones, it appeared that the proper regulation of EpCAM during 
differentiation is required to achieve the co-existence of EpCAM+ and EpCAM- cells. As a 
consequence, both, the entire loss and the forced overexpression resulted in disrupted 
differentiation. 
5.2 Mandatory segregation of EpCAM+ and EpCAM- clusters during EBs 
differentiation 
The presented study analyzed the patterns of EpCAM repression during the differentiation 
of mouse ESCs in a 3D-differentiation model. This EB-based model simulates various 
aspects of mouse embryogenesis in early stages and combines it with ability to genetically 
manipulate ESCs (Desbaillets et al., 2000). As such EBs derived from ESCs represent a 
useful in vitro simulation of an embryo comprised of internal meso- and ectoderm lineages, 
as well as an external visceral/primitive endoderm (Doetschman et al., 1985; Nishikawa, 
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Jakt and Era, 2007), which involves the forming of a primitive streak together with an 
anteroposterior axis through Wnt signaling (Nusse et al., 2008; ten Berge et al., 2008). In 
this model, EpCAM+ and EpCAM- cell clusters were segregated early in spontaneous 
differentiation, but remained in close proximity. The spatial separation of EpCAM+ and 
EpCAM- clusters could possibly be due to a direct effect of EpCAM on cell adhesion 
(Litvinov, Bakker, et al., 1994) or a negative effect on cell-cell contacts mediated by E-
cadherin (Litvinov et al., 1997). E-cadherin is a major adhesion molecule of mouse 
intestinal epithelial cells (Solanas et al., 2011) and during zebrafish gastrulation (Ulrich et 
al., 2005). In the mouse intestine, E-cadherin-mediated cell-cell adhesion must be 
abrogated in order to allow the migration of differentiating cells along the developing cripts 
(Solanas et al., 2011). Therefore, a similar requirement for a loss of EpCAM during the 
segregation of differentiating cells in EBs is conceivable, based on EpCAM’s own adhesion 
functions and on its effects on E-cadherin. 
5.3 Loss of EpCAM expression in pluripotent ESCs inhibits cardiomyocytes 
formation 
Based on the data in the present thesis, EpCAM over-expression imposes an inhibitory 
effect on the formation of cardiomyocytes, while a CRISPR/Cas9-mediated mutation of 
EpCAM demonstrated the necessity of endodermal EpCAM+ cells for the mesodermal 
lineage to generate cardiomyocytes (Figure 33). The expression of EpCAM supported the 
expression of Foxa2, Gata4, as well as alpha-fetoprotein (Afp) in endodermal cells derived 
from ESCs (Sarrach et al., 2018). In line with these findings, it has been reported that the 
development of cardiomyocytes required a physical contact of mesodermal progenitors 
with endodermal cells (Foley et al., 2006). More precisely, cardiomyocyte precursors need 
to be in physical contact with Gata4-producing Sox17+/EpCAM+ visceral endoderm, for the 
proper instruction of cardiomyocytes differentiation (Pal and Khanna, 2005; Holtzinger, 
Rosenfeld and Evans, 2010). A reported progression of Sox17+/EpCAM+ visceral 
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endodermal cells to hepatocytic progenitors (Holtzinger, Rosenfeld and Evans, 2010) 
further illustrated that EpCAM+ cells were mutually dependent on EpCAM- cells for their 
own differentiation. On that account, a high expression of EpCAM constitutes a major 
characteristic of hepatocytic stem cells in human (Schmelzer, 2007; Yoon et al., 2011). 
Furthermore, EpCAM acts as a de-repressor of the Wnt signaling cascade in zebrafish, 
which licenses cells to mature to functional hepatocytes (Lu et al., 2013). In line with this 
report, EpCAM over-expression in ESCs facilitated the expression of hepatocytic markers 
Afp and Fn1 (Sarrach et al., 2018). 
Fig. 33: Schematic illustration of EpCAM expression in differentiating ESCs 
Scheme shows that ESCs differentiated into either EpCAM+ endodermal progenitors or EpCAM- 
mesodermal progenitors during EBs differentiation. EpCAM+ endodermal progenitors and EpCAM- 
mesodermal progenitors in EBs were further differentiated into epithelial cells and cardiomyocytes 
respectively. Repression of EpCAM impairs the cardiomyocytes formation through the physical contact 
of endodermal and mesodermal progenitors. ERas as a downstream molecule of EpCAM has the 
capacity of complementing for the loss of EpCAM to support the formation of Gata4+ endodermal cells. 
Differentiation of EpCAM- ESCs was blocked at Mesp1+ stage. 
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5.4 EpCAM knockout ESCs clones are blocked in differentiation at the Mesp1+ stage 
The transcriptional factor Mesoderm Posterior BHLH Transcription Factor 1 (Mesp1) plays 
a central role in the development of the human cardiovascular system (Mazzotta et al., 
2016b). Accordingly, Mesp1 is required during early stages of the development of 
cardiomyocytes via the regulation of cardiac mesoderm at E6.5. As a result, the first heart 
field is formed, followed by the heart tube (Spater et al., 2014; Chen et al., 2015). During 
the migration process to form the heart crescent, down-regulation of Mesp1 by 
cardiomyocytes progenitors further facilitates the maturation to cardiomyocytes (Paige et 
al., 2015). 
In the present study, Mesp1 expression was greatly increased and Wnt5a was mildly 
enhanced at day 10 of spontaneous differentiation of EpCAM knockout clones. However, 
the expression of the central downstream regulators of cardiomyocytes differentiation 
Gata4, Nkx2.5, and Wnt11, as well as the cardiomyocytes marker -CAA was strongly 
reduced in EpCAM knockout clones at day 10 of spontaneous differentiation. At this time 
point, down-regulation of Mesp1 is supposed to be accomplished and is a prerequisite for 
cardiomyocytes differentiation in EBs. Hence, EpCAM knockout clones demonstrated a 
differentiation block at a Mesp1+ stage with a subsequent lack of further differentiation into 
cardiomyocytes (Figure 33). Due to a reduction of Wnt11, meso-endoderm cohesion is 
potentially affected (Ulrich et al., 2005), and mesodermal differentiation is ultimately 
blocked. 
5.5 Participation of the EpCAM/ERas/AKT axis in endo/ mesodermal differentiation 
The observed dual capacity of EpCAM to positively and negatively affect ESCs 
differentiation, might result from its interaction with the hyperactive Ras GTPase ERas, 
which reportedly affects the proliferation and teratogenic capacity of ESCs (Takahashi, 
Mitsui and Yamanaka, 2003; Lee et al., 2009a). Forced expression of EpCAM facilitated 
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the activating phosphorylation of the serine/threonine kinase AKT at serine473 in ESCs. In 
turns, ERas over-expression or activated AKT simulated the inhibitory function of EpCAM 
during the formation of cardiomyocytes, although with a reduced inhibitory ability compared 
with EpCAM. Our findings were corroborated by published results demonstrating that a 
loss of ERas is required in E7.5 embryos to facilitate the formation of the PS, as well as 
the generation of mesoderm (Zhao et al., 2015). Additionally, they reported on a retention 
of ERas in the endoderm of the same stage of gestation (Zhao et al., 2015). This finding 
further supports a role for the EpCAM/ERas signaling axis in the positive regulation of 
endodermal cells. 
EpCAM knockout clones, which showed a retained ability of cardiomyogenesis, revealed 
to be severely impaired in the formation of cardiomyocytes following an additional knockout 
of ERas. These findings suggested an ability of ERas to complement for the loss of EpCAM 
to support the formation of Gata4+ endodermal cells, which are required by cardiomyocytes 
progenitors for proper cardiomyocytes differentiation (Figure 33). An ERas interactor 
Galectin-1 has been shown to mediate anchorage of Ras proteins to the cell membrane 
(Paz et al., 2001) and to induce the mouse ESCs proliferation through the 
Src/ERas/Akt/mTOR signaling pathway (Lee et al., 2009b). Thus, the interaction of EpCAM 
with ERas was also likely to recruit the downstream molecules to ERas and induce the 
ERas/Akt signalling pathway. In line with the notion of an EpCAM/ERas signaling axis that 
is active in stem cells, EpCAM and ERas both positively impact on the reprogramming 
efficiency of somatic cells into iPS (Huang et al., 2011; Yu et al., 2014; Kuan et al., 2017). 
Therefore, EpCAM/ERas/AKT represents a novel signaling cascade in ESCs that supports 
endodermal cell differentiation, which are in turns required to instruct mesodermal 
differentiation to cardiomyocytes. 
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5.6 Dynamic EpCAM expression in ESCs differentiation and EMT process 
In non-pathological processes such as embryonic development, the formation of 
mesoderm from the epiblast (primitive ectoderm) occurs through the process of EMT, in 
which epiblast cells with an epithelial phenotype selectively lose surface proteins mostly 
involved in cell adhesion, and differentiate into mesenchyme (Rivera-Pérez, Mager and 
Magnuson, 2003; Mikawa et al., 2004; Migeotte et al., 2010; Nowotschin and A.-K. 
Hadjantonakis, 2010). During the differentiation of EBs, which simulates early embryonic 
development in vitro, EpCAM expression was retained in endodermal derived cells, but 
was repressed in mesodermal lineages (Sarrach et al., 2018), suggesting that the 
regulation of the EpCAM expression in non-pathological process e.g. ESCs differentiation 
was very likely in the context of EMT. In addition, the EpCAM dynamic expression is 
important for full differentiation of ESCs as balanced integration of EpCAM+ and EpCAM- 
cells is required (Sarrach et al., 2018). Accordingly, it was reported that EMT transcription 
factor Zeb1 can down-regulate the expression of both, E-cadherin and EpCAM, in 
zebrafish development (Vannier et al., 2013). 
In pathological processes, EpCAM exhibits a dynamic expression in cancer progression 
and shows a frequent loss in the course of EMT (Gorges et al., 2012; Gires and Stoecklein, 
2014; Wang et al., 2016). The EpCAM expression has reportedly served as a valuable 
marker for the evaluation of EMT heterogeneity, which is strongly associated with cancer 
progression (Liu et al., 2019). In head and neck cancers (HNSCC), EpCAM was a reliable 
marker to determine the epithelial differentiation status of cancer cells, as opposed to cells 
that have undergone a partial EMT, as has been demonstrated through single cell RNA-
sequencing of primary tumors and metastases (Puram et al., 2017). Results from our lab 
confirmed that a loss of EpCAM in HNSCC was correlated with worsened clinical outcome 
(Baumeister et al., 2018). Moreover, high expression of epidermal growth factor receptor 
EGFR in combination with low levels of EpCAM were associated with very poor prognosis 
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in HNSCCs, whereas EGFRlow/EpCAMhigh HNSCCs were defined by an outstandingly 
good prognosis (Pan et al., 2018). An underlying molecular mechanism for the observed 
discrepancy was proposed, where strong activation of EGFR induced EMT in HNSCC 
cells, and the extracellular domain of EpCAM (EpEX) acted as a novel EGFR ligand that 
counteracted EGF-induced EMT (Pan et al., 2018). Therefore, dynamic expression of 
EpCAM is highly involved in EMT during pathological processes, e.g. during cancer 
progression. 
5.7 RIP as a potential regulatory mechanism of the cell surface expression of 
EpCAM 
The accurate timing of the differential regulation of EpCAM in the 3D-model of ESCs 
differentiation has been addressed in previous sections in the discussion. The analysis of 
the expression of EpCAM in kinetics of EBs throughout spontaneous differentiation 
disclosed that EpCAM is completely lost in cellular subsets within a time frame of 12 h, 
typically between 3.5 and 4 days of differentiation (Sarrach et al., 2018). Interestingly, the 
down-regulation of transcripts levels of the EPCAM gene was slightly delayed compared 
to the abovementioned timing. In combination with a reported half-life of the EpCAM protein 
in cancer cells of 21 h (Munz et al., 2008), these data suggested that a post-translational 
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mechanism might be instrumental to shut down EpCAM expression within a short 
timeframe. 
Fig. 34: Schematic illustration of the regulated intramembrane proteolysis (RIP) and degradation 
of EpCAM.  
The Cleavage of EpCAM via RIP, including ADAM10/17 and -secretase involved. The cleavage 
products with degradation efficiency and half-lives of EpCTF in different cell lines are presented on 
scheme. 
 
Endocytosis and RIP act as two main mechanisms for cells to withdraw mouse and human 
EpCAM from the cell surface and to subsequently degrade it (Figure 34) (Hachmeister et 
al., 2013; Tsaktanis et al., 2015). Additionally, RIP constitutes the core of the molecular 
mechanism of signaling functions of EpCAM in stem cells and cancer cells. EpICD, which 
is generated through RIP of EpCAM, is instrumental in the activation of genes involved in 
the regulation of cell cycle, proliferation, fatty acid metabolism, differentiation and 
pluripotency-associated gene expression as described (Maetzel et al., 2009; Munz, 
Baeuerle and Gires, 2009; Lu et al., 2010; Lin et al., 2012; Chaves-Pérez et al., 2013; Kuan 
et al., 2017). On that account, it is important to understand the pace of the EpICD 
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generation in order to further interpret EpCAM’s function(s) in differentiation, as well as cell 
signaling. 
RIP involves the initial cleavage of EpCAM by - and/or -secretases within the 
extracellular domain to generate a soluble ectodomain EpEX together with an EpCTF 
fragment, which remains resident in the plasma membrane. This EpCTF is then a substrate 
for the -secretase complex that cleaves it at  and  sites within the transmembrane 
domain. Cleavage at -sites of mouse and human EpCTF releases a small extracellular 
fragment, which owing to its localization within EpCAM and to the mode of generation was 
termed A-like fragment, in analogy to the amyloidogenic A-fragment of amyloid 
precursor protein APP in Alzheimer’s syndrome (Hachmeister et al., 2013; Tsaktanis et al., 
2015). By now, little is known about the frequency of the first cleavage of EpCAM. A 
requirement for cell-cell contact to induce the initial cleavage was postulated and soluble 
EpEX was shown to be a ligand for full length EpCAM (Denzel et al., 2009; Maetzel et al., 
2009; Hachmeister et al., 2013). It is also conceivable that a so far unknown soluble or 
membrane-tethered ligand is required for the induction of EpEX shedding by - and/or -
secretases. However, such a ligand has not been identified and thus remains elusive. 
EpCAM regulation on cell surface is strongly associated with RIP, repression of RIP by 
using -secretase inhibition C3 lead to retention of full-length EpCAM in ESCs 
(Hachmeister et al., 2013). In contrast, membrane assays at pH4 which represents the pH 
optimum of -secretase demonstrate a significant decreases of EpCAM and a strong 
increases of EpCTF (Hachmeister et al., 2013). Similar results were also confirmed in 
human EpCAM with head and neck tumour cells (Tsaktanis et al., 2015). Recently, 
EGF/EGFR–triggered activation of RIP of EpCAM at the cell membrane has been reported, 
in which EGF treatment of an endometrial carcinoma line RL95-2 could induce the loss of 
EpEX at the cell membrane (Hsu et al., 2016). Unexpectedly, treatment of RL95-2 cells 
with EGF in combination with a -secretase inhibitor reverted EGF-mediated cleavage of 
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EpCAM and resulted in the retention of full-length EpCAM at the plasma membrane. 
However, those findings are in contradiction with our own published data, where EpCAM 
cleavage was not induced by EGF treatment and where the -secretase complex catalyzes 
EpCAM CTF, not full length EpCAM (Maetzel et al., 2009; Hachmeister et al., 2013; 
Tsaktanis et al., 2015). In fact, ectodomain shedding by the -secretase complex has, to 
the best of our knowledge, never been reported and generally contradicts the sequential 
cleavage during RIP. Therefore, it appears hardly conceivable that inhibition of -secretase 
has any direct effect on EGF/EGFR–mediated shedding of EpEX. 
Following the first cleavage of EpCAM, the signaling pace as well as the full degradation 
of EpCAM will be decided by the speed and rate of EpCTF proteolysis by -secretase, to 
release EpICD from plasma membrane. Thereafter, regulation of the stability of EpICD in 
cells is a means to control the extent and length of nuclear signaling and or other functions 
of EpCAM. Thus, the efficiency and pace of EpCTF cleavage by -secretase was 
addressed in-depth in the present thesis. 
5.8 Proteolysis of EpCTF by -secretase is a slow process 
Using biochemical approaches together with fluorescent protein-tagged variants of mouse 
and human EpCTF helped to trace and quantify EpCTF cleavage over time. This 
demonstrated that EpCTF is characterized by a 50% protein turnover in the time range of 
45 min to 5.3 h in various cell lines and for both, mouse and human EpCTF (Figure 34). 
Hence cleavage of EpCTF is a particularly slow process as compared to other classical 
enzymatic processes, such as for example 0.2083 s for the Renin-Angiotensinogen system 
and 0.0053 s for Chymosin k-Casein reaction (Vreeman et al., 1986; Nguyen et al., 2002). 
Similar findings were reported for the amyloid precursor protein (APP) CTF, which showed 
a 50% protein turnover of 2.9 h mediated by -secretase in vitro (Kamp et al., 2015), 
suggesting a consistently slow cleavage pace of the -secretase complex. 
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According to the swapping experiments performed in the present thesis, the provenance 
of EpCTF with respect to species did not affect proteolysis pace. Actually, proteolysis pace 
of EpCTF variants transfected into cells was dictated by cell lines, but not by the species 
of origin of the substrates. This was demonstrated by two major findings. Firstly, mouse 
and human EpCTFs had different half-lives depending on the cell lines in which they were 
expressed. Secondly, mouse and human EpCTF half-lives did not differ, when expressed 
in the same cell line. In order to investigate the molecular basis of these findings, evaluation 
of the aa sequences of mouse and human EpCAM was performed. The entire mouse 
EpCTF is 91% identical to human EpCTF (Figure 30). Importantly, the similarity between 
mouse and human EpCTF transmembrane domains, where the  and  cleavages take 
place, is as high as 96% (Figure 30), demonstrating a high similarity of aa sequences of 
mouse and human EpCTF, which could account for the molecular basis of similar half-lives 
dictated by cell lines. 
Moreover, endogenous EpCTF had a similar slow cleavage pace in carcinoma cells 
compared with exogenously expressed EpCTF variants, with 4.7 and 5.5 h, respectively 
(Figure 34). Therefore, our experimental system of exogenous EpCTF variants is an 
appropriate model to reflect the endogenous EpCTF cleavage process. 
In conclusion, these findings therefore strongly support the notion that -secretase 
represents the rate-limiting step rather than its substrate EpCTF. 
5.9 Sustained activation of EpCAM signaling via RIP and efficient shutdown by the 
proteasome 
The release of EpICD from the membrane-tethered EpCTF by -secretase is the final rate-
limiting step that is required to trigger intracellular signaling events mediated by EpCAM 
(Münz et al., 2004; Münz, Zeidler and Gires, 2005; Maetzel et al., 2009; Munz, Baeuerle 
and Gires, 2009; Chaves-Pérez et al., 2013). Given that EpCTF cleavage by -secretase 
is a particularly slow process, signaling by EpCAM through RIP is very unlikely to allow for 
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a swift reaction to extracellular cues, as is reported for receptors such as EGFR and others 
(Weng et al., 2004; Oda et al., 2005; Yarden and Shilo, 2007; Andersson, Sandberg and 
Lendahl, 2011). Therefore, the data presented in this thesis speak in favor of a more stable, 
steady signaling relying on EpICD in cancer cells (Maetzel et al., 2009; Chaves-Pérez et 
al., 2013) and in stem cells (Lu et al., 2010; Huang et al., 2011), rather than in favor of a 
rapid transmission of extracellular cues into cells to transiently active downstream genes. 
Additionally, the efficiency of EpICD degradation via the proteasome was as high as 94%, 
which could allow to regulate the strength of EpICD signals and, eventually, to strictly shut 
down the signaling mediated by EpICD. In addition, differences between malignant cells 
and normal cells in terms of EpICD nuclear localization (Maetzel et al., 2009) are likely to 
affect EpCAM signaling via RIP and may cause a signaling deficiency in normal tissues, 
which has been recently demonstrated in human liver cells (Gerlach et al., 2018).  
Taken all above, proteolysis of EpCTF by -secretase is a slow process and degradation 
of EpICD by the proteasome is highly efficient.  
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6. SUMMARY 
Embryonic development of mammalian species is a highly complex biological process, 
which is strongly associated with cellular dynamics and morphogenetic mechanisms. 
However, the current knowledge of precise timing of mouse embryogenesis is still 
incomplete. Fortunately, genetic manipulation techniques and cultivation of pluripotent 
ESCs in vitro could provide new opportunities to fill these knowledge gaps. In the present 
thesis, we are aiming at analyzing the spatiotemporal regulation of the epithelial cell 
adhesion molecule EpCAM in ESCs. 
In both E14TG2 and Bruce4 mouse embryonic stem cell lines, high levels of EpCAM 
expression is found at the pluripotent stage, while EpCAM expression is significantly 
reduced after 3D spontaneous differentiation, which closely mimics the early mouse 
embryogenesis. Interestingly, this dynamic of EpCAM expression is strictly related to the 
three germ layers of embryoid bodies (EBs). The expression of EpCAM in nascent visceral 
endoderm was confirmed by the results, showing a co-localization of EpCAM with Foxa2 
in marginal cells of EBs. Immunofluorescence double-staining of EpCAM and vimentin 
displayed a mutually exclusive expression pattern in EBs, demonstrating an absence of 
EpCAM in mesodermal cells. Genetic knockout of EpCAM in pluripotent ESCs inhibited 
cardiomyocytes formation. Additionally, cardiomyocytes precursors need a physical 
contact with Gata4-producing Sox17+/EpCAM+ visceral endoderm for the proper 
differentiation of cardiomyocytes (Pal and Khanna, 2005; Holtzinger, Rosenfeld and 
Evans, 2010). Therefore, EpCAM is required for the full differentiation of ESCs. Moreover, 
a differentiation block at a Mesp1+ stage was determined in absence of EpCAM. ERas, a 
Ras protein expressed in ESCs, was co-precipitated with EpCAM in ESCs lysates. 
Knockout of ERas led to further impairment of the contracting ability of EpCAM knockout-
derived EBs, while EpCAM and ERas overexpression both inhibited cardiomyocytes 
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formation. Thus, these findings describe a novel signaling cascade of EpCAM/ERas/AKT 
to support the proper differentiation of ESCs, including to cardiomyocytes. 
EpCAM is completely lost in mesodermal cells within 12 h during spontaneous 
differentiation of EBs. Interestingly, the down-regulation of EpCAM at the transcriptional 
level was slightly delayed compared to protein loss. In addition, the half-life of the EpCAM 
protein is 21 h (Munz et al., 2008). Thus, these findings suggested a post-translational 
mechanism that is in place to shut down EpCAM expression within a short timeframe. At 
the cell membrane, EpCAM could undergo RIP to generate EpEX and EpCTF fragment. 
The EpCTF fragment will be further cleaved by the -secretase complex to generate 
EpICD, which is important for EpCAM signaling. Therefore, RIP is a potential regulatory 
post-translational mechanism for EpCAM expression. The protein turnover of EpCTF was 
assessed using biochemical and time-lapse imaging techniques in combination with 
fluorescence-tagged versions of human and mouse EpCTF. By doing so, a time range of 
45 min to 5.3 h for a 50% turnover was determined in various cell lines, for both mouse 
and human EpCTF. However, this EpCTF proteolysis by -secretase is a particularly slow 
process compared to other classical enzymatic processes such as 0.2083 s for Renin-
Angiotensinogen system. Such a slow enzymatic processes is dictated by the cell line, but 
not by the substrate EpCTF, as defined by swapping experiments across species and 
EpCTF variants. Accordingly, a 96% similarity of aa sequence was revealed between 
mouse and human EpCAM transmembrane domain, where  cleavage takes place. Given 
that the EpCTF cleavage by -secretase is a particularly slow process, EpCAM signaling 
by RIP is very likely to be a sustained, steady signaling, relying on EpICD in cancer cells 
and ESCs. Moreover, EpICD degradation via proteasome was as high as 94%. Hence, 
such an efficient degradation could strictly shut down the EpCAM signaling. Thus, EpCAM 
is slowly cleaved by -secretase followed by efficient proteasomal degradation of EpICD 
to control EpCAM expression and functionality.  
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7. ZUSAMMENFASSUNG 
Die Embryonalentwicklung von Säugetieren ist ein hochkomplexer biologischer Prozess, 
der stark mit der Zelldynamik und den morphogenetischen Mechanismen verbunden ist. 
Aktuell ist jedoch wenig über das genaue Timing der Mausembryogenese bekannt. 
Genetische Manipulationstechniken und die Kultivierung pluripotenter ESCs in vitro, bieten 
neue Möglichkeiten diese Wissenslücken zu schließen. In der vorliegenden Arbeit wollen 
wir die räumlich-zeitliche Regulation des Epithelzelladhäsionsmoleküls EpCAM in ESCs 
untersuchen. 
Sowohl die embryonalen E14-TG2 als auch die Bruce4 Maus Stammzelllinien weisen 
eine hohe EpCAM Expression im pluripotenten Stadium auf, während die Expression nach 
spontaner 3D-Differenzierung signifikant reduziert ist. Dies bildet ein in vitro Modell, 
welches die frühe Mausembryogenese stark nachahmt. Interessanterweise hängt diese 
Dynamik der EpCAM Expression eng mit der Ausbildung der drei Keimschichten in 
embryoid bodies (EBs) zusammen. Die Expression von EpCAM im entstehenden 
viszeralen Endoderm wurde durch eine Ko-Lokalisation von EpCAM mit Foxa2 in 
Randzellen von EBs gezeigt. Eine Doppelfärbung von EpCAM und Vimentin in EBs zeigt 
ein sich ausschließendes Expressionsmuster, wobei Vimentin-exprimierende 
mesodermale Zellen kein EpCAM exprimierten. Ein genetischer Knockout von EpCAM in 
pluripotenten ESCs hemmte die Bildung von Kardiomyozyten. Zusätzlich benötigen 
Kardiomyozyten-Vorläufer einen physischen Kontakt mit Gata4-produzierendem 
Sox17+/EpCAM+ Zellen des Viszeralendoderms, um zu Kardiomyozyten heranzureifen 
(Pal and Khanna, 2005; Holtzinger, Rosenfeld and Evans, 2010). Daher ist EpCAM für die 
vollständige Differenzierung von ESCs erforderlich. Darüber hinaus wurde in Abwesenheit 
von EpCAM ein Differenzierungsblock von Kardiomyozyten im Mesp1+ Stadium bestimmt. 
ERas, ein in ESCs exprimiertes Ras-Protein, wurde als Interaktionspartner von EpCAM 
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charaktierisiert. Der Knockout von ERas in ESCs führte zu einer weiteren Beeinträchtigung 
der Kontraktionsfähigkeit von EpCAM Knockout EBs, während die Überexpression von 
EpCAM und ERas die Bildung von Kardiomyozyten inhibierte. Daher beschreiben diese 
Ergebnisse eine neuartige Signalkaskade von EpCAM/ERas/AKT, die für eine 
ordnungsgemäße Differenzierung von ESCs, einschließlich der Bildung von 
Kardiomyozyten, benötigt wird. 
Während der spontanen Differenzierung von EBs geht EpCAM in mesodermalen Zellen 
innerhalb von 12 Stunden vollständig verloren. Interessanterweise war die 
Herunterregulierung von EpCAM auf Transkriptionsebene im Vergleich zum Proteinverlust 
etwas verzögert. Außerdem beträgt die Halbwertszeit des EpCAM-Proteins 21 Stunden 
(Munz et al., 2008). Diese Ergebnisse legen daher einen posttranslationalen Mechanismus 
nahe, mit dem die EpCAM Expression innerhalb eines kurzen Zeitraums eingestellt 
werden kann. An der Zellmembran könnte EpCAM durch regulierte 
Intramembranproteolyse (RIP) gespalten werden, um ein EpEX (EpCAM extracellular 
domain) und ein EpCTF (EpCAM C-terminal fragment) zu erzeugen. Das entstandene 
EpCTF Fragment wird durch den -Sekretasenkomplex weiter gespalten, um EpICD 
(EpCAM intracellular domain) zu erzeugen, was für die EpCAM Signalübertragung wichtig 
ist. Daher ist RIP ein potenzieller regulatorischer posttranslationaler Mechanismus der 
EpCAM-Regulierung. Der Proteinumsatz von EpCTF wurde unter Verwendung von 
Zeitraffer Bildgebungstechniken an Lebendzellen in Kombination mit 
fluoreszenzmarkierten Versionen von menschlichem und mousem EpCTF gemessen. Auf 
diese Weise wurde die Proteinspaltung (50% Umsatz) gemessen, welche in 
verschiedenen Zelllinien, sowohl für mouses als auch für humanes EpCAM, 45 Min. bis 
5.3 Std. betrug. Diese EpCTF-Proteolyse durch die -Sekretase ist jedoch ein besonders 
langsamer Prozess. Andere klassische enzymatische Prozesse, wie z.B. das Renin-
Angiotensinogen-System benötigen lediglich 0.2083 Sekunden. Die langsame 
enzymatische Spaltung von EpCTF wird von der -Sekretase bestimmt, nicht aber von 
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dem Substrat EpCTF. Dementsprechend wurde eine 96%-ige Homologie in der Sequenz 
zwischen der mousen und der humanen EpCAM Transmembrandomäne festgestellt, in 
der die Spaltung stattfindet. Da die EpCTF-Spaltung durch die -Sekretase ein besonders 
langsamer Prozess ist, ist es sehr wahrscheinlich, dass die EpCAM-Signalübertragung 
durch RIP eine anhaltende Signalübertragung darstellt, die in Krebszellen und ESCs auf 
EpICD beruht. Darüber hinaus lag der EpICD Abbau über das Proteasom bei 94%. Daher 
könnte eine solche effiziente Degradierung die EpCAM Signalwege streng regulieren. 
Zusammenfassend wird EpCAM langsam durch die -Sekretase gespalten, gefolgt von 
einem effizienten proteasomalen Abbau von EpICD, welcher die Expression und 
Funktionalität von EpCAM kontrolliert. 
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8. APPENDIX 
ABBREVATIONS 
°C degree Celsius 
aa amino acids 
APS ammonium persulfate 
bp base pairs 
BSA bovine serum albumin 
cDNA complementary DNA 
DMEM Dulbecco`s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
ECL enhanced chemiluminescence 
EDTA ethylene diamine tetra acetic acid 
EMT epithelial to mesenchymal transition 
EpCAM epithelial cell adhesion molecule 
EpCTF              C-terminal fragment of EpCAM 
EpICD intracellular domain of EpCAM 
GFP green fluorescent protein 
FACS fluorescence activated cell sorting 
FC flow cytometry 
FCS fetal calf serum 
IH immunohistochemistry 
IF immunofluorescence 
KCl potassium chloride 
kDa kilo Dalton 
L liter 
M molar 
mA milli ampere 
max maximal 
mg milligram 
µg microgram 
ng                     Nanogram 
min minute 
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mL milliliter 
µL microliter 
mM millimolar 
µM micromolar 
nM                    Nanomolar 
mRNA messenger RNA 
NaCl sodium chloride 
N-term N-terminus 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PBST PBS + Tween-20 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PVDF polyvinylidene fluoride 
qRT-PCR quantitative Real Time PCR 
rcf relative centrifugal force 
RIP regulated intramembrane proteolysis 
RNA ribonucleic acid 
rpm revolutions per minute 
RT reverse transcriptase 
SDS-PAGE sodium dodecyl sulfate polyacrylamide  
SILAC stable isotope labeling by/with amino acids in cell  
TEMED Tetramethylenediamine 
TRIS tris (hydroxyl methyl) aminomethane 
Triton X-100 polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl  
WB western blot 
w/o without 
YFP yellow fluorescent protein 
 alpha 
 beta 
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